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Treatment of diabetes mellitus is mainly focused on glycaemic control regulated by insulin and 
takes place in insulin sensitive tissues like skeletal muscle which accounts for 75% of glucose 
metabolism. Plant derived compounds that have anti-diabetic potential are currently being 
investigated for diabetes treatment as they are cheap and non-toxic. Oleanolic acid (OA), a 
triterpene found in a wide variety of plants has been shown to have anti-diabetic effects but its 
mechanism of action, especially on the insulin signalling cascade has not been fully elucidated. 
The aim of the present study was to investigate the effects of OA on the PI3K/Akt insulin 
signalling cascade in skeletal muscle and skin of streptozotocin induced diabetic male Sprague-
Dawley rats. Male Sprague-Dawley rats (non-diabetic and diabetic) were treated with insulin 
(4IU/ kg bw), OA (80 mg/kg bw) and a combination of OA + insulin in an acute and sub-chronic 
study. The study showed that OA does not reduce blood glucose levels in type 1 diabetic rats but 
enhances insulin stimulated hypoglycaemic effects. In the acute study OA was shown to activate 
Akt and dephosphorylate GS in skeletal muscle of streptozotocin induced diabetic rats. In the 
sub-chronic study OA and OA + insulin increased expression of GS in skeletal muscle of 
diabetic rats. GP expression was decreased by OA and OA + insulin treatments in skeletal 
muscle whilst in skin it was increased by both treatments.  OA increased both GS and GP in 
skeletal muscle whilst in skin they were decreased. OA + insulin treatment increased GS and 
decreased GP activities in skeletal muscle and increased activity of both enzymes in skin of 
diabetic rats.  OA increased the amount of glycogen in both muscle and skin whilst OA + insulin 
reduced the amount of glycogen. OA  and OA + insulin treatment showed some protective 
effects against liver and muscle damage as there were reductions in serum LDH, ALT and AST 
levels. In conclusion, oleanolic acid in synergy with insulin can enhance activation of the insulin 
signalling pathway and there was evidence of OA activation of insulin signaling enzymes 






Diabetes mellitus is one of the major diseases with a high mortality rate worldwide. It is caused 
by pancreatic β cell dysfunction and insulin resistance in peripheral tissues, and characterized by 
hyperglycaemia. People suffering from insulin dependent diabetes mellitus need insulin 
injections daily. The main role of insulin in the body is to lower blood glucose levels. Since the 
commercial production of insulin started, different insulin analogues have been produced 
namely; long acting insulin analogues, rapid acting insulin analogues and premixed analogues. 
These analogues mimic physiological insulin but with different pharmacodynamic effects. 
Insulin like many hormones in the body binds to specific receptors on cell surfaces triggering 
activation of a signalling cascade in that cell. In skeletal muscle (which accounts for 
approximately 75% of glucose metabolism) insulin leads to activation of the PI3-K/Akt 
(Phosphoinositide - 3 kinase/ protein kinase B) cascade that leads to increased glucose uptake 
from the blood and glycogen synthesis. The presence and activation of the upstream proteins of 
the PI3-K/Akt cascade has been observed in the skin but not much information is known about 
the downstream processes in relation to glycogen metabolism. Due to the side effects and 
inconvenience of taking synthetic drugs a lot of work is now being conducted into finding plant 
derived compounds that are less toxic but have anti-diabetic potential. Triterpenoids have been 
observed to have anti-diabetic activities. Oleanolic acid, a triterpenoid, has been observed to 
have hypoglycaemic activity and is already used clinically in the treatment of liver disorders. 
The aim of this study is to determine the effects of oleanolic acid on the PI3-K/Akt signalling 
cascade in muscle and skin of streptozotocin-induced diabetic rats. 
1.1. Diabetes mellitus 
Diabetes mellitus is a heterogeneous disease characterized by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both (Jacobsen et al., 2009). According to recent statistics from the 
World Health Organization (WHO), about 3 million deaths per year are caused by diabetes and 
its complications. Characteristic symptoms of mild diabetes are thirst, polydipsia, and polyuria 
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and weight loss. In severe cases, ketoacidosis or hyperglycaemic-hyperosmolar states may occur 
and lead to disturbances of consciousness, coma and death unless treated appropriately (Kuzuya 
et al., 2002).  
 
There are two types of diabetes, Type 1 and Type II diabetes. Type 1 diabetes (insulin-dependent 
Diabetes mellitus) usually begins in childhood and is characterized by atrophy of pancreatic β 
cells (Kuzuya et al., 2002; Varshosaz, 2007). Type 1 diabetes mellitus (T1DM) which accounts 
for 5-10% of diabetic patients is caused by extensive β-cell destruction, resulting in a decrease or 
cessation of insulin production, thus patients are absolutely dependent on exogenous insulin 
(Adams et al., 2011; Varshosaz, 2007). The condition can further be classified as immune-
mediated diabetes (type 1A and idiopathic diabetes (type 1B) which affects the minority of 
patients (Adams et al., 2011). Type II diabetes mellitus (T2DM) (non-insulin-dependent diabetes 
mellitus) is far more common and generally occurs in patients older than 40 years. Patients 
normally have normal or high levels of insulin in their blood but exhibit low response to insulin. 
T2DM can be treated by controlling the diet of the patient although exogenous insulin can be 
used to supplement that produced by the pancreatic β cells (Varshosaz, 2007).Although T1DM 
and T2DM originate from different pathogenetic causes the effects are similar these being 
hyperglycaemia and diabetic microvascular complications (Jang et al., 2010). 
 
Over time diabetes leads to complications involving small blood vessels that cause retinopathy, 
nephropathy and neuropathy, which lead to visual disturbance, renal failure and gangrene 
respectively (Kuzuya et al., 2002). T2DM has also been implicated in cardiovascular diseases 
that include atherosclerotic cardiovascular artery disease, stroke and diabetic cardiomyopathy 
(Raza and Movahed, 2003). The complications of diabetes mellitus are the main causes for its 
high mortality and morbidity rate (Kuzuya et al., 2002). Hyperglycemia is the main cause of the 
development and progression of these microvascular and macrovascular complications, 
suggesting that its control can prevent or reverse diabetic complications. Thus diabetes treatment 
mainly focuses on glycaemia control (DaSilva et al., 2010). 
 
In healthy individuals, plasma glucose levels remain within the normal range despite large 
fluctuations in nutritional intake and physical activity. After healthy individuals eat, their plasma 
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glucose concentration increases rapidly, peaks in 30-60 minutes and returns to basal 
concentrations within 2-3 hours (Herbst and Hirsch, 2002). Initial insulin response to glucose 
intake during a meal is characterized by a rapid increase in insulin secretion that is completed 
within 10 minutes followed by a sustained secretion of insulin above basal rates that can last for 
hours. Patients with T1DM who no longer produce adequate endogenous insulin need 
replacement that mimics these phases of insulin production (Herbst and Hirsch, 2002).   
1.1.1. Insulin 
Various studies have revealed that many tissues in the body respond to insulin with effects on 
carbohydrate, lipids, protein and ion metabolism (Thirone et al., 2006).Thus in addition to the 
classical insulin responsive tissues (liver, muscle and adipose), insulin elicits responses in the 
kidney, brain and β cells (Thirone et al., 2006). The primary role of insulin is to remove excess 
glucose from the circulatory system. In mammals glucose is stored as glycogen and the 
conversion of glucose into glycogen in muscle and liver, and to fat in adipose tissue is a key 
event in the maintenance of glucose homeostasis (Newgard et al., 2000). In humans 80% of 
glycogen is stored in the skeletal muscle and its synthesis plays a key role in insulin action and 
glycaemic control (Jensen et al., 2011b; Jiao et al., 2001). Insulin is released from the pancreatic 
β cells in response to increased blood glucose and amino acids following ingestion of meals and 
exerts its actions through binding to specific receptors present on many cells of the body 
(Aronoff et al., 2004). There are three ways by which insulin controls postprandial glucose. 
Insulin signals the cells of insulin sensitive peripheral tissues, primarily skeletal muscle, to 
increase their uptake of glucose (Aronoff et al., 2004). Secondly insulin promotes glycogenesis 
synthesis in the liver. Thirdly insulin inhibits glucagon secretion from pancreatic α cells, thus 
signalling the liver to stop producing glucose via glycogenolysis and gluconeogenesis (Aronoff 
et al., 2004). Other actions of insulin include the stimulation of fat synthesis, promotion of 
triglyceride storage in fat cells, promotion of protein synthesis in the liver and muscle, and 
proliferation of cell growth (Aronoff et al., 2004).  
Insulin is secreted as an inactive single-chain precursor, preproinsulin, with a signal sequence 
that directs its passage into secretory vesicles (Rains and Jain, 2011). Proteolytic removal of this 
signal sequence results in the formation of proinsulin. In response to an increase in blood glucose 
or amino acid concentration, proinsulin is secreted and converted into active insulin by special 
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proteases (Rains and Jain, 2011). The active form of insulin consists of two polypeptide chains 
(Figure 1.1). The A chain consists of 21 residues (A1-A21) and the B chain consists of 30 
residues (B1-B30) (Derewenda et al., 1989).The two chains are held together by two disulfide 
bonds with another disulfide bond connecting A6 and A11 (Derewenda et al., 1989; Rains and 
Jain, 2011). There are also numerous non-covalent interactions between the amino acids of the 
two chains (Derewenda et al., 1989). 
 
Figure 1.1: Amino acid sequence of insulin (adapted from Berg et al. (2002). 
1.1.1.1. Insulin analogues 
Insulin analogues are designed to mimic physiologic insulin profiles through improved 
pharmacokinetic characteristics which result in either rapid or prolonged pharmacodynamic 
effects (Hartman, 2008). Upon subcutaneous injection, insulin molecules form a depot from 
which absorption into the systemic circulation occurs. All insulin molecules have a tendency to 
self-aggregate into hexameric complexes and these clusters must dissociate into dimers and 
monomers to diffuse through interstitial fluid, penetrate the capillary wall, and enter the 
bloodstream (Hartman, 2008). The unique pharmacological features of individual insulin analog 
preparations largely  involve the rate of hexamer dissociation and the subsequent movement of 
free insulin into the circulation (Hartman, 2008). The three types of insulin analogues are the 
long acting, short acting and premixed. Premixed analogues are a mixture of the long acting and 
rapid acting insulin analogues mixed in differing ratios. They are more convenient as they are a 
single product and have a further advantage of providing coverage from the beginning of a 
meal(Gómez-Pérez and Rull, 2005). 
 
Rapid acting insulin analogues e.g. lyspro and aspart, are designed to offer a more rapid onset of 
action and shorter duration of activity than human insulin by making minor modifications to one 
or two amino acids on the insulin molecule  (Gómez-Pérez and Rull, 2005; Hartman, 2008). The 
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analogues reach peaks higher than those obtained with regular insulin(Gómez-Pérez and Rull, 
2005).  The structural changes weaken the tendency to self-associate into hexamers, thereby 
facilitating more rapid absorption. The molecular changes do not alter the biological properties 
of the analogs in terms of binding to the insulin receptor, and the insulin analogues retain the 
same glucose lowering effects as human insulin (Hartman, 2008).  
 
Examples of long acting insulin analogues are glargine and detemir. Glargine has got amino acid 
modifications in both chains. In the A chain Asn
21
 is substituted by glycine and the B chain is 
elongated at the C-terminus by addition of two arginine residues(Gómez-Pérez and Rull, 2005; 
Valla, 2010). Glargine is a molecule with a changed isoelectric point towards neutral, bearing 
decreased solubility at physiological pH (Valla, 2010). This causes precipitation after injection in 
subcutaneous tissue, stabilization of insulin hexamers, delay of their dissociation, and steady 
absorption into the circulation. This analogue bears a stable serum concentration without 
pronounced peaks and significantly elongated duration of action which covers the patient for 24 
hours (Valla, 2010). Detemir is characterized by acylation of myristic acid to the Lys
29
 on the B 
chain and deletion Thr
30
 in the B chain(Gómez-Pérez and Rull, 2005; Valla, 2010). Its action is 
achieved through delayed resorption caused by increased self-association and reversible albumin 
binding at the injection site. Further albumin binding causes buffering of insulin concentration. A 
flat, prolonged pharmacodynamic profile is achieved which provides a metabolic profile for 
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Figure 1.2: Hypoglycaemic action of different drugs and their target organs (Adapted from Hui et al. (2009). 
Figure 1.2 shows the oral glucose-lowering agents in T2DM which include α-glucosidase 
inhibitors, metiglinides, sulphonylureas, biguanides and thiazolidinediones.  α-Glucosidase 
inhibitors delay carbohydrate absorption, metiglinides and sulphonylureas increase insulin 
supply, and biguanides and thiazolidineodines enhance insulin action (Anselmino, 2009). The 
mechanism of action of α-glucosidase inhibitors relies on the reduction of glucose uptake by the 
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duodenum and jejunum through  sites of competitive inhibition of the brush border α-glucosidase 
enzyme (Anselmino, 2009). Metiglinides and sulphonylureas are insulin secretagouges and 
depend on functioning pancreatic β-cells receptors to which they bind and enhance basal and 
postprandial glucose stimulated insulin secretion (Donner, 2006). Their effects  might also be 
enhanced by peripheral effects that may include reduction of hepatic insulin clearance 
(Anselmino, 2009). Biguanides (e.g. metformin) depend on the availability of insulin. The drug 
decreases glucose production enhancing hepatic insulin response (via gluconeogenesis 
inhibition) (Anselmino, 2009)and to a lesser extent increase glucose utilization by skeletal 
muscle (Donner, 2006). Other effects include decreased appetite and food absorption and 
reduction in low-density lipoprotein cholesterol levels leading to weight loss (Anselmino, 2009; 
Donner, 2006). Thiazolidineodines action depends on the presence of insulin and resistance to its 
action (Anselmino, 2009). They act by enhancing insulin action in muscle and fat without 
increasing insulin secretion (Donner, 2006). 
1.2. Glycogen metabolism in skeletal muscle and skin 
In the fed-fasted transition, glycogen stores represent a major source of energy and serve to 
protect against hypoglycemia (Newgard et al., 2000). Glycogen concentrations depend on 
glycogen synthesis and degradation which are tightly regulated by hormones and metabolic 
signals via modulation of glycogen synthase and glycogen phosphorylase enzymatic activities 
(Jiao et al., 2001; Newgard et al., 2000; Toole and Cohen, 2007). Other rate-limiting steps in 
glycogen synthesis are increased glucose uptake via the insulin stimulated glucose transporter 
GLUT4 (Toole and Cohen, 2007) and the activity of hexokinase (James et al., 1998). In the rat 
model of diabetes, an increase in rate of glycogen synthesis in response to hyperglycaemia 
occurs via the dephosphorylation of glycogen synthase. However, there is no  increase in 
glucose-6-phosphate levels (James et al., 1998). The insulin mediated PI3K/Akt signalling 
cascade regulates glucose homeostasis in the main insulin responsive tissues in the body. 
The skeletal muscle is the major site for the action of insulin on  glucose uptake and utilization 
(Jensen et al., 2011b; Meynial-Denisa et al., 2005), with approximately 75% of insulin-
dependent-glucose disposal taking place in this tissue (Saltiel and Kahn, 2001). The GLUT4 
transporters are the main transporters responsible for glucose uptake in skeletal muscle (Jensen et 
al., 2011b). Hyperglycemia increases blood glucose levels leading to an increase in skeletal 
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muscle glucose disposal (Björnholm and Zierath, 2005). The major stimulators of glucose 
transporters in skeletal muscle are insulin, insulin-like growth factors, muscle contraction and 
cellular stress (Zierath and Kawano, 2003). In the muscle glucose is converted into glycogen. 
Glucose-6-phosphate (G-6-P) is converted to glucose-1-phosphate (G-1-P) by 
phosphoglucomutase  (PGM) and finally into UDP-glucose by UDP-glucose pyrophosphate 
(UDPGPP) (Ferrer et al., 2003). UDP-glucose is the glycosyl donor in the reaction catalyzed by 
glycogen synthase (Ferrer et al., 2003). 
The skin is not considered as a major insulin-responsive tissue, thus little information is known 
about the effects of the insulin family of proteins on regulation of metabolic processes in skin 
(Shen et al., 2000). Studies by Shen et al. (2000) indicated that insulin differentially regulated 
glucose uptake as well as expression and translocation of specific transporters in the skin. 
Functional insulin receptors (IR) have been expressed in cultured murine skin keratinocytes 
(Sadagurski et al., 2007). It has also been shown that insulin increases the glucose transport rate, 
induces proliferation, and enhances differentiation in epidermal cells (Sadagurski et al., 2007). 
Lack of IR expression abolishes these insulin-induced processes and there are several skin 
pathologies associated with impaired insulin signalling, e.g. wound healing (Sadagurski et al., 
2007). Pelegrinelli and co-workers in 2001 demonstrated that proteins that are involved in early 
steps of insulin action are expressed in skin of intact rats and are quickly activated after insulin 
stimulation. 
 
1.3. PI3-K/Akt signalling cascade 
Figure 1.3 shows a schematic presentation of how insulin regulates the PI3K/Akt signalling 
pathway. Insulin binds to the extracellular α subunits of the insulin receptor, leading to 
intracellular autophosphorylation of the transmembrane β subunits and enhancement of their 
intrinsic tyrosine kinase activity (Watson and Pessin, 2001). The activated receptor, recruits and 
phosphorylates the substrate molecules, insulin receptor substrates 1 / 2 (IRS1/IRS2), adapter 
molecules that play a major role in coupling the insulin signal to the PI3K-Akt kinases (Fröjdö et 
al., 2009). Tyrosine phosphorylated IRS1/2 recruit the heterodimeric 85/p110 PI3K at the 
plasmamembrane, where it produces the lipid second messenger Phosphatidylinositol (3, 4, 5)-
triphosphate (PIP3), which activates a serine/threonine phosphorylation cascade of PH (plekstrin 
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homology) domain containing proteins; phosphoinositide dependent protein kinase-1 (PDK1), 
Akt and atypical protein kinase C (aPKC) ζ/ λ.  
 
Figure 1.3: Schematic representation of the PI3K/Akt signalling pathway enzymes during glucose 
homeostasis (Fröjdö et al., 2009). 
These proteins are recruited at the plasma membrane by binding to PIP3 and thereafter, PDK1 
phosphorylates Akt and aPKCs on a threonine residue located in the activation loop of the 
catalytic domain, causing their activation (Fröjdö et al., 2009). Activated Akt targets GSK-3 and 
AS160. Akt-mediated phosphorylation on Ser
9
 inactivates glycogen synthase kinase 3 (GSK-3). 
This inactivation, in parallel to protein phosphatase-1 (PP1) activation, relieves the inhibitory 
phosphorylation of glycogen synthase (GS), which becomes activated and promotes glycogen 
synthesis. Akt also regulates the insulin-stimulated translocation of the glucose transporter 
GLUT4 at the plasma membrane, resulting in increased glucose uptake (Fröjdö et al., 2009). 
This pathway involves an inhibitory phosphorylation of the RabGTPase activating protein 
AS160. Inhibition of AS160 favours the GTP-loaded state of Rab and relieves an inhibitory 
effect towards GLUT4 translocation from intracellular compartments to the plasma membrane. 
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In addition to the role of Akt in controlling GLUT4 translocation, aPKCs act in parallel to /or can 
even be substitutive for Akt (Fröjdö et al., 2009). 
1.3.1. Insulin receptor (IR) 
Insulin receptors (IR) are found in virtually all vertebrate tissues and belong to a family of 
growth factor receptors, all with protein tyrosine kinase activity (Björnholm and Zierath, 2005; 
Pelegrinelli et al., 2001). The IR is a heterotetrameric membrane glycoprotein consisting of two 
α-subunits and two β-subunits that function as allosteric enzymes in which the α-subunit inhibits 
the tyrosine kinase activity of the β-subunit (Björnholm and Zierath, 2005; Saltiel and Kahn, 
2001). Insulin binds to the extracellular α-subunit of the receptor and induces a conformational 
change that brings the α-subunits closer together leading to a rapid autophosphorylation of the 
receptor (Björnholm and Zierath, 2005; Pessin and Saltiel, 2000). The coming together of the α-
subunits removes the β subunit inhibitory effect. Upon ligand binding and receptor dimerization, 
the kinase domain in one half of the dimer phosphorylates cytoplasmic tyrosine residues on the 
half of the receptor dimer. This results in a large increase in the catalytic activity of the receptor. 
Upon autophosphorylation of tyrosine residues at position 1158, 1162 and 1163 in the activation  
loop, this region swings out of the catalytic site and is stabilized in a conformation that gives 
unrestricted access to substrates (Nystrom and Quon, 1999). Tyrosine sites are phosphorylated 
on the IR creating a recognition motif for the phosphotyrosine-binding domain of the IRSs 
(insulin receptor substrates) (Björnholm and Zierath, 2005). In addition to tyrosine 
phosphorylation the IR proteins can undergo serine phosphorylation which may attenuate 
signalling by decreasing insulin-stimulated tyrosine phosphorylation (Saltiel and Kahn, 2001). 
Insulin action is also attenuated by protein tyrosine phosphatases (PTPs) which catalyze the rapid 
dephosphorylation of the receptor and its substances (Saltiel and Kahn, 2001). 
 
1.3.2. Insulin receptor substrates (IRSs) 
 
The insulin receptor substrates (IRSs) family of proteins are phosphorylated by the activated 
insulin receptors (Virkamäki et al., 1999). IRS1 is the best characterized of the IRSs, and lacks 
catalytic activity, but in order to effect the many biological activities of insulin, it serves as a 
docking protein to which different signalling proteins such as phosphatidylinositide-3-kinase 
11 
 
(PI3-K) bind through Src homology 2 (SH2) domains (Alonso et al., 2006). The IRS proteins 
contain a NH2-terminal PH-domain and COOH-terminal PTB (phosphotyrosine binding) domain 
(Lee and White, 2004; Thirone et al., 2006; Virkamäki et al., 1999). The PH domain is involved 
in targeting of the IRS proteins to the membrane and the insulin receptor whilst the PTB domain 
is critical for recognition of the NPXpY (asparagine-proline-any amino acid-phosphotyrosine) 
sequence in the insulin receptor (Virkamäki et al., 1999). IRS1 also contains at least 21-22 
tyrosine phosphorylation sites and also more than 30 serine/threonine phosphorylation sites 
(Björnholm and Zierath, 2005). A significant increase in the Ser/Thr phosphorylation of IRS 
proteins has been shown to act as a negative feedback-control mechanism that uncouples IRS 
proteins from their upstream and downstream effectors and therefore terminates signal 
transduction in response to insulin. IRS1 Ser/Thr phosphorylation is a potential molecular 
mechanism for insulin resistance (Alonso et al., 2006). 
 
1.3.3. Phosphoinositide 3-kinase (PI3-K) 
 
PI3-K plays an important role in many insulin-regulated mitogenic and metabolic processes 
including glucose uptake, general and growth-specific protein synthesis and glycogen synthesis 
(Pelegrinelli et al., 2001). The enzyme is activated by insulin, insulin-like growth factor and 
other growth factors. It is a heterodimeric lipid kinase capable of phosphorylating the D-3 
position on the inositol ring in phosphoinositides (Shepherd, 2005). PI3-K consists of an 85kDa 
regulatory subunit (that binds to the IRSs) that associates with a 110 kDa catalytic subunit 
(phosphorylates phosphatidylinositol’s) (Björnholm and Zierath, 2005; Lee and White, 2004; 
Shepherd, 2005). PI3-K phosphorylates phosphatidylinositol 4, 5-biphosphate (PIP2) to 
phosphatidylinositol (3, 4, 5)-triphosphate (PIP3). Inhibition of PI3-K blocks the formation of 
PIP3 within the cell and leads to the inhibition of several cellular events, most importantly GLUT 
4 translocation, and thereby inhibiting insulin-stimulated glucose transport in the insulin 
sensitive tissues. Activation of PI3-K with insulin though is insufficient for insulin stimulated 





1.3.4. Phosphoinositide-dependent protein kinase-1 (PDK1) 
PDK1 plays a central role in activating the AGC (cAMP-dependent, cGMP-dependent, protein 
kinase C) kinases subfamily members that include protein kinase B (PKB), p70 ribosomal S6 
kinase (p70 S6K), serum and glucocorticoid-induced kinase (SGK) and protein kinase C (PKC) 
isoforms (Biondi, 2004; Biondi et al., 2000). It is a 556-amino acid containing enzyme 
possessing a kinase domain at its N terminus and a PH domain at its C-terminus which interacts 
with PIP3 and PIP2 (Mora et al., 2004). PDK1 appears to possess a hydrophobic binding site in 
the small lobe of its kinase catalytic domain that regulates its activity as well its interaction with 
substrates (Biondi et al., 2000). Akt also contains a PH domain and thus interacts with PIP3/PIP2. 
This allows for co-localization of Akt and PDK1 at the plasma membrane and enabling PDK1 to 
phosphorylate and activate Akt (Biondi, 2004; Mora et al., 2004). PDK1 phosphorylates Akt at 
Thr
308
 and the equivalent residues on PKC isoforms (Biondi et al., 2000).  
1.3.5. Protein kinase B (Akt) 
Akt is a serine/ threonine kinase that belongs to the AGC subfamily of kinases. Three isoforms 
have been identified, Akt 1, Akt 2 and Akt 3, all of which are ubiquitously expressed. The 
protein contains three functional domains: an N-terminal PH domain, a central kinase domain 
and a C-terminal regulatory domain containing the hydrophobic motif (HM) phosphorylation 
site. Full activation of Akt 1 requires phosphorylation of two specific sites, Thr
308
 in the 
activation loop of the kinase domain and Ser
473 
in the HM domain (Fayard et al., 2005).  The 
unphosphorylated form of Akt is inactive and PDK1 phosphorylation stimulates its activity by at 
least 100-fold. Phosphorylation of Ser
473
 augments the activity of PDK1 phosphorylated Akt by 
7- to 10 fold  (Yang et al., 2002).The mechanism for phosphorylation of Ser
473
 is unclear, but 
PDK2 is believed to be involved(Björnholm and Zierath, 2005). PKB is activated as a 
consequence of the stimulation of PI3-K and the generation of PIP3. PIP3 interacts with the PH 
domain of Akt, recruiting the kinase to the plasma membrane and exposing a pair of serine and 
threonine residues for phosphorylation by PDK1 (Yang et al., 2002).  
 
 




GSK-3 is a serine/threonine protein kinase that is highly conserved and is ubiquitously 
expressed. It exists in 2 isoforms, GSK-3α (51kDa) and GSK-3β (47 kDa) (Patel et al., 2008). 
GSK-3 plays a role in a wide variety of cellular functions, including several components of fuel 
metabolism and transcriptional regulation (Sakamoto and Goodyear, 2002). A major regulatory 
mechanism for GSK-3α and GSK-3β activity occurs via phosphorylation of serine residues near 
the amino terminus (Ser
21
 on GSK-3α, Ser
9
 on GSK-3β), which results in deactivation of the 
enzyme. Insulin stimulation of PI3-kinase leads to Akt activation, leading to phosphorylation of 
GSK-3 on Ser
9/21
, and deactivation of GSK3. Deactivation of GSK-3 is then thought to promote 
activation of glycogen synthase (Sakamoto and Goodyear, 2002). 
 
1.3.7. Glycogen synthase (GS) 
 
Glycogen synthase catalyzes the incorporation of UDP-glucose into glycogen as illustrated in 
Figure 1.4. Phosphorylation of multiple sites on GS results in progressive inactivation whereas 
insulin stimulates the dephosphorylation of glycogen synthase resulting in maximal stimulation 
of glycogen synthesis (Brady et al., 1999). Increase in intracellular levels of glucose, UDP-
glucose, and glucose-6-phosphate which is an allosteric effector for the activation of GS 
(Mandarino et al., 1987), also contribute to the regulation of GS (Brady et al., 1999). Activation 
of glycogen-targeted protein phosphatase 1 (PP1) by insulin produces the dephosphorylation of 
both glycogen synthase and phosphorylase resulting in enzymatic activation of GS and inhibition 
of GP (Brady et al., 1999). Insulin also decreases GSK-3 activity, which phosphorylates and 
inactivates GS. The relative contribution of PP1 activation versus GSK-3 inactivation in the 
regulation of glycogen synthase by insulin remains uncertain, and might vary among cell types 




Figure 1.4: Schematic of the muscle glycogen synthesis pathway indicating the allosteric control of GS by 
glucose 6-phosphate (G6P). GT (glucose transporter); HK (hexokinase); Gi (intracellular glucose); GSase 
(glycogen synthase) Adapted from Shulman et al. (1995) 
 
A correlation of glucose-6-phosphate with glycogen synthesis in rat muscle shows that, when 
insulin is increased from 1 to 100 mU/L, the rate of glycogen synthesis is increased but the 
content of glucose-6-phosphate remains unaltered, suggesting a direct effect of insulin on 
glycogen synthase (Dimitriadis et al., 2011). However this effect of insulin would not result 
unless glucose transport and hexokinase activity are both increased and the activity of glycogen 
phosphorylase is strongly inhibited by insulin (Dimitriadis et al., 2011). 
 
1.3.8. Atypical PKCs (aPKCs) 
Studies in animals have implicated aPKCs (ubiquitously expressed and evolutionarily conserved 
in many different species) in insulin-stimulated GLUT4 translocation and glucose transport in 
muscle and adipose tissue. In human isolated adipocytes, expression of PKC-ζ or PKC-λ 
increased glucose transport (Fröjdö et al., 2009). In lean, non-diabetic human subjects, insulin 
stimulation leads to a two fold increase in aPKC activity in muscle and adipose tissue. A positive 
relationship was also seen between insulin-stimulated PKC- ζ / λ  activity and insulin-stimulated 
glucose disposal rate (Fröjdö et al., 2009). The activation of aPKCs is unclear although there are 
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two mechanisms that are thought to be involved (Liu et al., 2006). APKCs are activated in two 
steps: unfolding the folded state, then autophosphorylation of specific threonine residues of the 
aPKCs. Inactivated aPKCs exist in a folded state in which auto-inhibitory pseudo-substrate 
sequences at aPKCs NH2-terminal covers the substrate binding site of catalytic domain at the 
COOH-terminal, not only hampering autophosphorylation of specific substrates, but also of 
specific threonine residue of aPKCs (Liu et al., 2006). The second mechanism is through the 
disassembly of freed kinase domain by the ubiquitin-proteasome system (Liu et al., 2006). After 
unfolding and activation, limited hydrolysis of aPKCs subunits, produce a short lived constituted 
active M-type kinases (PKM) that are not inhibited by pseudosubstrate-mediated auto-inhibition 
(Liu et al., 2006).   
1.3.9. Akt substrate of 160 kDa (AS160) 
 
AS160 is a 160-kDa substrate of Akt which was first identified in 3T3L1 adipocytes. It is a 
protein containing a RabGTPase-activating protein (GAP) domain. Phosphorylation of AS160 is 
required for the insulin induced translocation of GLUT4 to the plasma membrane in 3T3L1 
adipocytes (Karlsson et al., 2005). The substrate has been shown to regulate GLUT 4 
translocation in insulin sensitive 3T3-L1 adipocytes and L6 myoblasts. AS160 also contains two 
phosphotyrosine-binding domains and multiple putative phosphorylation sites, including six 
phospho-Akt substrate (PAS) targeted by Akt, AMPK, and potentially other upstream kinases 
(Kramer et al., 2006). GLUT4 vesicles are dynamic complexes that are directed by GTP-bound 
Rab proteins and other molecular chaperones. Thus, AS160 GAP activity could inactivate a 
critical, still unidentified Rab protein as part of the mechanism for controlling basal GLUT4 
trafficking (Kramer et al., 2006). When cells are treated with insulin, however, AS160 is rapidly 
phosphorylated at PAS (primer activation signal) motifs and dissociates from GLUT4 vesicles. 
This is associated with accelerated rates of GLUT4 vesicular exocytosis, such that GLUT4 
manifests predominantly at the cell surface and enhances glucose transport (Kramer et al., 2006). 
 
1.3.10. GLUT 4 transporters 
GLUT 4 is one of 13 sugar transporter proteins (GLUT1-GLUT12, and HMIT (Highest 
Myocardial Ischemic Threshold) encoded in the human genome. These transporters facilitate 
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hexose transport across cell membranes through an ATP-independent, facilitative diffusion 
mechanism (Huang and Czech, 2007). GLUT 4 is expressed primarily in muscle and adipose 
tissue and is the major insulin-responsive glucose transporter isoform (Watson and Pessin, 2001). 
The transporter displays mostly intracellular disposition in the unstimulated state that is acutely 
redistributed to the plasma membrane in response to insulin and other stimuli (Huang and Czech, 
2007). GLUT4 contains unique sequences in its N- and COOH- terminal cytoplasmic domains 
that direct its characteristic membrane trafficking capability. These include a distinctive N-
terminal sequence with a potentially critical phenylalanine residue as well as dileucine and acidic 
motifs in the COOH terminus. These motifs likely govern kinetic aspects of both endocytosis 
and exocytosis in a continuously recycling system (Huang and Czech, 2007). In the basal state 
GLUT 4 cycles slowly between the plasma membrane and multiple multicellular compartments, 
with the vast majority of the transporter residing within the cell interior. Activation of the insulin 
receptor stimulates the rate of GLUT 4 vesicle exocytosis, concomitant with a smaller decrease 
in the rate of GLUT 4 endocytosis, resulting in increased glucose uptake (Brady et al., 1999). 
The exocytic steps regulated by insulin potentially include stimulation of the formation of GLUT 
4 transport vesicles, mobilization of a pool of GLUT 4 vesicles, increased docking at the plasma 
membrane of GLUT 4 vesicles, and/or increased fusion of GLUT 4 vesicles with the plasma 
membrane (Gonzalez and McGraw, 2006) 
 
1.4. Regulation of the PI3-K/Akt insulin signalling cascade 
 
1.4.1. Glycogen phosphorylase (GP) 
 
GP is a dimer of identical 842-residue (97 kDa) subunits that catalyzes the  rate-controlling step 
in glycogen degradation (Voet et al., 2006). It catalyzes the conversion of α (1-4) linked glucose 
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The enzyme is regulated both by allosteric interactions and by covalent modifications 
(phosphorylation and dephosphorylation). Phosphorylase a is the activated form and has a 
phosphoryl group esterified to Ser
14
 and the dephosphorylated form is called phosphorylase b 
(Voet et al., 2006). Phosphorylase b is activated by phosphorylase kinase through 
phosphorylation at Ser
14
. Phosphorylase kinase is in-turn activated by protein kinase A (PKA) 
(Voet et al., 2006). Phosphorylase kinase is 1300 kDa protein with four non-identical subunits 
(α, β, γ, δ), with the γ subunit containing the catalytic site and the other subunits having 
regulatory functions. The enzyme is activated by Ca
2+
 and by the phosphorylation of its α and β 
subunits by PKA (Voet et al., 2006). Type 1 diabetic humans and STZ-induced diabetic rats 
exhibit increased expression of (GP) gene expression in muscle. This decreases in rats after 
insulin treatment suggesting that the GP gene is negatively regulated by glucose uptake (Wallis 
et al., 1998). For optimal glycogen deposition to occur it is suggested that it is not only necessary 
to activate glycogen synthase but also the proportion of glycogen phosphorylase in the active 
phosphorylated form must decrease (Brau et al., 1997).  
 
1.4.2. Protein Tyrosine Phosphatase (PTP) 
PTPs are involved in the negative regulation of receptor tyrosine kinases (RTKs) of which the 
insulin receptor belongs to (Östman and Böhmer, 2001). PTPs are characterized by the presence 
of a signature motif, H-C-X-X-G-X-X-R. They are further categorized as dual-specificity 
phosphatases (DSPs) and classical PTPs (Tonks and Neel, 2001). Classical PTPs contain one or 
two ‘PTP domains’, conserved stretches of 240-250 amino acids that surround the signature 
motif (Tonks and Neel, 2001). The structure of classical PTPs, especially the depth of the active 
site cleft renders the specificity of PTPs for pTyr residues, compared with pSer or pThr (Tonks 
and Neel, 2001). PTP1B is a 435 amino acids form of 50 kDa, with an N-terminal catalytic 
domain (PTP domain), followed by two proline rich domains. It localizes in the endoplasmic 
reticulum through a small hydrophobic stretch found in its C terminus (Dubé and Tremblay, 
2005). DSPs belong to a heterogeneous subgroup of the type-1 cysteine-based PTP superfamily. 
These phosphatases can dephosphorylate both phosphotyrosine and 
phosphoserine/phosphothreonine residues within one substrate (Patterson et al., 2009). PTP1B 
has been implicated in the attenuation of several protein tyrosine kinase (PTK) signalling 
pathways including the insulin receptor (Dubé and Tremblay, 2005; Elchebly et al., 1999). It has 
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been discovered that mice in which PTP1B gene was deleted had reduced plasma insulin and 
glucose levels. This was ascribed to enhanced insulin signalling through the insulin receptor and 
insulin receptor substrate-1 in the absence PTP1B (Hooft-van-Huijsduijnen et al., 2002). 
1.4.3. Protein phosphatase 1 (PP1) 
PP1 catalyzes the insulin-dependent dephosphorylation of glycogen synthase and also 
inactivation of glycogen phosphorylase, further contributing to stimulation of glycogen 
deposition (Newgard et al., 2000). The enzyme removes the phosphoryl groups from glycogen 
phosphorylase a and the α and β subunits of phosphorylase kinase (Voet et al., 2006). In muscle 
the catalytic subunit of the protein phosphatase-1 is called PP1c. In its active state it is bound to a 
124 kDa glycogen-binding protein, GM, forming the PP1c-GM phosphatase haloenzyme (PP1-G) 
(Aggen et al., 2000). The activity PP1c and its affinity for the GM subunit are regulated by 
phosphorylation of the GM at two separate sites. PP1c is activated by insulin-stimulated protein 
kinase (a homolog of PKA and the γ subunit of phosphorylase kinase) at site 1. PKA (which can 
also phosphorylate site 1) then activates PPIc at a second site, site 2. This phosphorylation causes 
PP1c to be released into the cytoplasm where it cannot dephosphorylate the glycogen-bound 
enzymes of glycogen metabolism (Voet et al., 2006). 
1.5. Oleanolic acid 
Oleanolic acid (3β-hydroxy-olea-12-en-28-oic acid) shown in Figure 1.5, is a triterpenoid 
compound which exists widely in natural plants in the form of free acid or aglycones from 
triterpenoid spooning (Liu, 1995) and is marketed in China as an oral drug for human liver 
disorders (Song et al., 2006).  The compound has been isolated from more than 1620 plant 
species and is mainly prevalent in plants belonging to the Oleaceae family. The main source of 
commercial oleanolic acid is the olive (Olea europaea) from which the compound derives its 
name (Pollier and Goossens, 2012). Insulin and synthetic agents used in the treatment of diabetes 
are good in controlling hyperglycaemia, but these drugs have prominent side effects such as 
hypoglycaemia, dropsy, drug resistance and weight gain (Gao et al., 2009). Compounds derived 
from natural resources have been determined to function in the regulation of diabetic 
pathophysiological signalling pathways (Liu et al., 2010) and  being less toxic  they have 




Figure 1.5: Structure of oleanolic acid (Melo et al., 2010) 
1.5.1. Pharmacology of oleanolic acid 
OA has been used as an oral remedy for the treatment of acute and chronic liver diseases in 
China (Feng et al., 2011). In a study conducted by Feng et al. (2011), it was shown that OA 
might have a beneficial effect on the vascular system by up-regulating heme oxygenase-1 (HO-
1) via the PI3K/Akt and ERK (extracellular signal-regulated kinase) pathways. Due to its low 
solubility, OA has low bioavailability in the system. In vitro Caco-2 cell permeation studies 
showed that OA was a low permeability compound with no directional effects suggesting a low 
in vivo absorption mediated by a passive diffusion  (Jeong et al., 2007). In vivo experiments on 
rats confirmed that OA was poorly absorbed with an absolute oral bioavailability of  0.7% (Jeong 
et al., 2007). An experiment conducted by Jeong et al. (2009) showed that OA was not stable in 
rat liver microsomes in the presence of NADPH as 60% of the OA disappeared at the end of the 
1 hour incubation period. This suggested that the compound is extensively metabolized in rat 
liver (Jeong et al., 2007).   
1.5.2. Hypoglycaemic effects of oleanolic acid 
Gao and co-workers in 2009 showed a significant hypoglycaemic activity of OA, derived from 
Ligustrum lucidum Ait, on alloxan induced type II diabetic rats over a period of 40 days at doses 
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of 60 and 100 mg/kg of body weight. Hypoglycaemic activity has also been shown in adrenaline-
induced type II diabetic mice which had hyperglycaemia due to increased hepatic glycogenolysis 
(Chen et al., 2006). OA was administered orally at 100 mg/kg/day for 7 days and on the last day 
blood glucose levels were measured after administering adrenaline intravenously. The in vivo 
test results showed that OA effectively inhibited the increase of fasted plasma glucose of diabetic 
mice induced by adrenaline (Chen et al., 2006). In experiments conducted by Wang and co-
workers in 2011, preventive and therapeutic treatment of streptozotocin induced type I diabetic 
rats with 100 mg/kg of body weight resulted in glycaemic control. Animals that were treated 
with OA as a preventive measure had normal fasting blood glucose levels throughout the 
experiment whilst those treated after diabetic induction had fasting blood glucose levels dropping 
to normal after a week (Wang et al., 2011). 
1.6. Oleanolic acid regulation of the PI3-K/Akt insulin signalling pathway  
Oleanolic acid has been shown to be a natural inhibitor of glycogen phosphorylase (GP) in vitro, 
the enzyme responsible for glycogen breakdown to produce glucose and other metabolites for 
energy supply (Chen et al., 2006; Cheng et al., 2009; Cheng et al., 2010). Chen and coworkers in 
2006 outlined the importance of OA being a therapeutic drug. Firstly OA may lower blood 
glucose levels in part by inhibiting GP, thereby reducing hepatic glucose production. Secondly  
OA is already a safe non-prescription drug used for the treatment of hepatitis and may find its 
new clinical uses in treating diseases caused by defects in glycogen metabolism (Chen et al., 
2006; Cheng et al., 2010). Finally OA is widely distributed in the plant kingdom and easily 
available in bulk. Chemical modifications of OA could further mechanistic studies and drug 
development (Chen et al., 2006; Cheng et al., 2010).  
Oleanolic acid has also been found to be a competitive inhibitor of protein tyrosine 
phosphatase1B (PTP1B) (Liu et al., 2010). PTP1B is a negative regulator of  insulin signalling, 
and inhibits insulin signalling by dephosphorylating and deactivating IRTK and IRS (Liu et al., 
2010). Studies carried out with knock-out mice suggest that lack of PTP-1B enzyme would result 
in activated insulin receptors, improved sensitivity to insulin, and stimulated glucose uptake 
(Ramírez-Espinosa et al., 2011). Oleanolic acid has been reported to be an inhibitor of PTP-1B 
with an IC50 value of 3.02 µM. The inhibition mechanism was determined by studying the effects 
of increasing inhibitors concentration on main kinetics parameters, Km and Vmax. The results 
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suggested that the inhibition mechanism of oleanolic acid could be a linear mixed-type inhibition 
model, suggesting a possible binding in a different cavity from the catalytic site (Ramírez-
Espinosa et al., 2011). A derivative of oleanolic acid 3-ß-(2-carboxybenzoly)-oleanolic acid 
(NPLC441) was also found to be a competitive inhibitor of PTP1B, potently stimulated glucose 
uptake through multi-target pathways  as it could increase IR and Akt phosphorylation and 
upregulate GLUT4 expression (Liu et al., 2010).  
1.7. Rationale of study 
Diabetes mellitus leads to disturbances in insulin mediated glucose metabolism and is 
characterized by hyperglycaemia. Treatment of the disease focuses on glycaemic control. Natural 
compounds have been investigated and OA has be shown to be anti-diabetic (Gao et al., 2009). 
Skeletal muscle account for most of the body’s insulin stimulated glucose uptake (Saltiel and 
Kahn, 2001). The largest organ in the body is the skin which can make up to 15% of the body 
weight and thus a reduction in the glucose uptake would contribute to increased blood glucose 
levels (Spravchikov et al., 2001). Glucose metabolism in the skin can therefore play an important 
role in glycaemic control. Glucose taken up by cells is mainly converted into glycogen with GS 
and GP being the two regulatory enzymes that catalyze the rate-limiting steps of glycogen 
synthesis and degradation respectively (Rao et al., 1995). An understanding of how OA affects 
the insulin signalling cascade in vivo is not well elucidated. Therefore the study investigated the 











1.8. Aims and Objectives 
Aim: To determine the effects of OA on the PI3-K/Akt insulin signalling cascade in muscle and 
skin of streptozotocin induced diabetic male Sprague-Dawley rats. 
Objectives 
1. To determine the acute effect of OA administration on the expression of PI3-K/Akt 
insulin signalling cascade enzymes using SDS-PAGE Western Blot analysis. 
2. To determine, in sub-chronic studies, the effect of OA on the expression of the PI3-K/Akt 
insulin signalling cascade enzymes using SDS-PAGE Western Blot analysis. 
3. To measure the activities of glycogen phosphorylase and glycogen synthase in skeletal 
muscle and skin after treatment with OA in sub-chronic studies. 
4. To determine the effect of OA on muscle and skin glycogen. 
5. To measure serum lactate dehydrogenase (LDH), aspartate transaminase (AST) and 















METHODS AND MATERIALS 
2.1. MATERIALS 
2.1.1. Chemicals 
The oleanolic acid (OA) was purchased from Shaanxi King Stone Enterprise Company Limited, 
China and SIGMA-ALDRICH, South Africa.  The insulin (Humalog Mix50 Kwikpen) was 
purchased from Eli Lilly, South Africa The following chemicals were purchased from SIGMA- 
ALDRICH, South Africa: Ethylene diaminetetraacetic acid (EDTA), Sodium pyrophosphate 
(Na4P2O7), Sodium fluoride (NaF), Sodium orthovanadate (Na3VO4), Nonidet P-40, Leupeptin 
hemisulphate, Benzamidine hydrochloride hydrate, Phenylmethanesulfonylfluoride (PMSF), 
Dithiothreitol (DTT), Glycogen, 3-(N-morpholino) propanesulfonic acid (MOPS), 2-(N-
morpholino) ethanesulfonic acid (MES), α-D-Glucose 1-phosphate disodium salt hydrate, 
Glucose-6-phosphate disodium salt, Adenosine monophosphate, Uridinediphosphoglucose 
(UDPG), Glycerol, Bromophenol blue, Glycine, Acrylamide, N’N’- bis- methylene-acrylamide, 
Dimethyl sulfoxide (DMSO), Potassium chloride (KCl), Phenol solution, di-Potassium hydrogen 
orthophosphate (K2HPO4), Methanol, β-Mercaptoethanol, Potassium dihydrogen phosphate 
(KH2PO4) and Tween-20, Streptozotocin (STZ), Sodium chloride (NaCl), Triton-X 100  and 
Bovine serum albumin (BSA). Copper sulphate (CuSO4.H2O), Potassium iodide (KI), Sodium 
hydroxide (NaOH), Citric acid, Sodium citrate, Disodium hydrogen phosphate (Na2HPO4), 
Sulphuric acid, Potassium sodium tartate (KNaC4H4O4.H2O), Sodium sulphate (NaSO4), 
Hydrochloric acid (HCl), Potassium hydroxide (KOH), were purchased from MERCK, South 
Africa. Sodium dodecyl sulphate (SDS), Tris, Ammonium persulphate, N, N, N, N -
Tetramethylethylenediamine (TEMED) and 10X Tris/Glycine/SDS buffer were purchased from 
either BIORAD, South Africa or SIGMA-ALDRICH, South Africa. The antibodies for 
Glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH), anti-phospho-Akt, anti-phospho-GS 
and anti-GS were obtained from Cell Signalling Technology, South Africa. The anti-GP and 
anti-phospho-IRS1antibodies were purchased from ABCAM, South Africa whereas the 
secondary antibodies, Goat anti-Rabbit IgG Dylight 650 conjugate and Goat anti-Rabbit IgG 
Alkaline phosphatase conjugate were purchased from Thermo Scientific, South Africa and from 
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Cglucose-1-phosphate were purchased from BIOTREND, Germany. 
2.1.2. Animals (Ethical clearance number 081/11/Animal and 018/12/Animal) 
Male Sprague-Dawley rats (250-300 g body weight) were procured from the Biomedical 
Resource Unit (BRU) at Westville Campus of the University of KwaZulu-Natal. The animals 
were fed a commercially available rat chow diet chow (Meadows, Pietermaritzburg, South 
Africa), ad libitum for the entire experimental period. Drinking water was provided for all the 
animals ad libitum for the duration of the experiment. The animals were maintained according to 
the rules and regulations of the University of KwaZulu-Natal (UKZN) Animal Ethics 
Committee.  
2.2 METHODS 
2.2.1. Preparation of OA 
An oleanolic acid (OA) suspension was prepared in a vehicle containing DMSO: physiological saline 
solution (1:2). The OA was first suspended in DMSO and then diluted by an equal volume of saline. 
Different lower concentrations of DMSO (10% and 25%) were tried until the one that provided the 
most uniform slurry was found. 
 
2.2.2. Induction of diabetes 
Diabetes was induced with a single intraperitoneal (I.P) injection of streptozotocin (STZ, 60 mg/kg. 
body weight) dissolved in freshly prepared cold 0.1 M citrate buffer (pH 4.5). Animals with a fasting 
blood glucose concentration of ≥18 mM after one week were considered as stable diabetic animals 
before experimental procedures began. The fasting blood glucose in tail vein blood was measured 
using an ACCU CHEK Aviva Nano glucometer, (USA). 
 
2.2.3. Preliminary studies to investigate the blood glucose lowering effect of OA 
Male Sprague-Dawley rats were divided into 4 groups (n = 8): diabetic control (DC), diabetic OA 
(DO), diabetic insulin (DI) and diabetic OA + insulin (DOI). Each group was further divided into 2 
sets (n = 4) and an oral glucose tolerance test (OGTT) was conducted. In the first set the animals 
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were fasted for 18 hours and then given glucose orally (0.86 g/kg body weight). The DC group did 
not receive any treatment, whilst the DO group was given 80 mg/kg body weight of OA orally. The 
DI group was given a subcutaneous injection of insulin (4 IU/kg body weight) and the DOI group 
was given 80 mg/kg body weight of OA orally + subcutaneous injection of insulin (4 IU/ kg body 
weight). Blood glucose levels were measured at time 0, 15, 30, 60 and 120 minutes using an ACCU 
CHEK Aviva Nano glucometer, (USA). The second set of animals were not fasted or given a glucose 
load before OGTT was performed but received the same treatment.  
 
2.2.4. Acute effect of OA on the insulin signalling cascade.  
Male Sprague-Dawley rats were divided into 8 groups as illustrated in Table 2.1 below: non-diabetic 
control (NC), non-diabetic insulin (NI), non-diabetic OA (NO), non-diabetic OA + insulin (NOI), 
diabetic control (DC), diabetic insulin (DI), diabetic OA (DO) and diabetic OA + insulin (DOI). The 
NC and the DC groups were orally dosed with the vehicle composed of DMSO: physiological saline 
(3 ml/kg body weight). The NI and DI groups were treated with insulin subcutaneously 4 IU/kg body 
weight. The NO and DO groups were treated with OA (80 mg/kg body weight). The NOI and DOI 
groups were treated with both OA and insulin. All the groups were euthanized at the following time 
intervals after giving them their treatment: (n = 2) at 5, 15, and 30 minutes and (n = 6) for 60 














Table 2.1: Representation of the different treatments for the acute studies 
Male Sprague-Dawley rats Non- diabetic  Diabetic 







































Treatment periods 15 minute (n = 2) 
30 minutes (n = 2) 
60 minutes (n = 6) 
Rats euthanized after treatment periods. Skeletal muscle and skin collected snap frozen and stored at -20 ºC for further 
analysis. 
p.o; oral, s.c; subcutaneous, bw; body weight, IU; insulin units 
 
2.2.5. Sub-chronic studies 
For acute studies there were 7 day and 14 day treatments periods. In each treatment period there 
were 8 groups (n = 6) of male Sprague-Dawley rats designated as follows: non-diabetic control 
(NC), non-diabetic insulin (NI), non-diabetic OA (NO), non-diabetic  OA + insulin (NOI), diabetic 
control (DC), diabetic insulin (DI), diabetic OA (DO) and diabetic OA + insulin (DOI). The NC and 
the DC groups were orally dosed with the vehicle composed of DMSO: physiological saline (3 ml/kg 
body weight). The NI the DI groups were treated with insulin subcutaneously (4 IU/kg body weight). 
The NO and DO groups were treated with OA (80 mg/kg body weight). The NOI and DOI groups 
were treated with both OA and insulin. All the groups were treated daily and were euthanized after 7 
or 14 days. The skin and skeletal muscle was harvested, snap frozen and stored at -20 ⁰C for further 
analysis. Blood was also collected in Vacutainer blood collection tubes containing thrombin and kept 
on ice. Serum was obtained after blood that was kept on ice for 2 hours was centrifuged at 3000 rpm 
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for 10 minutes using a Heraeus Labofuge 200 centrifuge, Thermoscientific (USA). The clear serum 
was collected in Eppendorf tubes and stored at 20 ⁰C for further analysis 
 
2.2.6. Tissue processing for western blots 
Skeletal muscle was processed according to a method adapted from Sakamoto et al. (2003). 
Muscles  samples were homogenized using an OMNI TH2 tissue homogenizer (USA) at 35 000 
rpm in 4 volumes of  lysis buffer (20 mM Tris, pH 7.5, 5 mM EDTA, 10 mM Na4P2O7, 100 mM 
NaF, 2 mM Na3VO4, 1% Nonidet P-40, 7 µM leupeptin, 3 mM benzamidine, and 1 mM PMSF. 
Homogenates were then centrifuged at 14000 g for 10 min at 4 °C using a Beckman Coulter J26-
XPI centrifuge (USA) and the supernatant collected. The protein concentrations of the 
supernatants were determined by the Biuret method with BSA as a standard.  
 
The skin tissue was processed according to a method adapted from Pelegrinelli et al. (2001). 
Skin was homogenized in 4 volumes of buffer containing 1% Triton-X 100, 100 mM Tris, pH 
7.4, containing 100 mM , Na4P2O7, 100 mM NaF, 10 mM EDTA, 10 mM Na3VO4, 2 mM PMSF 
and 3 mM benzamidine, using an OMNI tissue homogenizer (USA) at 35 000 rpm at 4 ⁰C. The 
homogenates were centrifuged at 27216 g and 4 ⁰C for 45 minutes using a Beckman Coulter J26-
XPI centrifuge (USA). The supernatant was collected and protein concentration was determined 
using the Biuret method with BSA as a standard. 
 
2.2.7. SDS-PAGE and Western Blot analysis 
SDS-PAGE was conducted according to the method adapted from Laemmli (1970). Equal 
amounts of proteins were resolved by SDS-PAGE using a Bio-Rad Mini - PROTEAN 3 
Electrophoresis cell, BIORAD (South Africa) and BG-VerMINI Marine Electrophoresis cell 
from Vacutec, South Africa. The protein was electrophoresed in Tris/Glycine/SDS buffer, pH 8.3 
at 110 V. The proteins on the gels were transferred to nitrocellulose membranes in 
Tris/Glycine/Methanol buffer, pH 8.3 using a Bio-Rad Trans-Blot Electrophoretic Transfer Cell, 
BIORAD (South Africa) run at 100V for 2 hours. The membranes were blocked with Phosphate 
buffered saline (10 mM Phosphate, 137 mM NaCl, 2,7 mM KCl, pH 7.4)  containing 0.1% 
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Tween 20 and  1%  BSA, at 4 ⁰C overnight. The membranes were incubated in Phosphate 
buffered saline containing 0.1% Tween 20 (PBST) with the indicated antibodies (anti-GAPDH 
which acts as a loading control, anti-phospho-Akt, anti-phospho-GS, anti-GS and anti-GP) for 1 
hour at room temperature. Membranes were probed with Goat anti-Rabbit IgG Dylight 650 
conjugate  (1:5000) and Goat anti-Rabbit IgG Alkaline phosphatase conjugate (1:1500 in PBST 
for 1 hour at room temperature, and antibody-bound proteins were visualized using a Syngene G-
BOX Chem XR5, Vacutec (South Africa). Images were captured using the GeneSys software 
and the bands were quantified using GeneTools analysis software. 
 
2.2.8. Determination of enzyme activity 
 
2.2.8.1. Glycogen synthase activity assay 
The glycogen synthase assay was adapted from Mandarino et al. (1987). Samples were weighed 
still frozen and immediately homogenized (50 mg tissue/ml) in an ice-cold buffer consisting of 2 
mM DTT, 20 mM NaF, 20 mM EDTA, and 50 mM potassium phosphate buffer, pH 7.4 using an 
OMNI tissue homogenizer (USA) at 35 000 rpm. The homogenates were centrifuged at 20000 g 
for 20 minutes using a Beckman Coulter J26-XPI centrifuge (USA). Protein concentration was 
determined using the Folin-Lowry method and BSA used as a standard. The supernatant was 
diluted 1:5 in a buffer consisting of 20 mM EDTA, 25 mM NaF and 50 mM Tris-HCl, pH 7.8. 
Reactions were started by the addition of 50 µl of the sample to 50 µl of a reaction mixture 
composed of 20 mM EDTA, 25 mM NaF, 50 mM Tris-HCl (pH 7.8), 1% glycogen, 1 µCi/ml 
[U-
14
C]uridinediphosphate glucose (UDPG), 5 mM UDPG, and 10 mM glucose-6-phosphate 
(G6P). The reaction mixture was incubated for 20 minutes at 30 ⁰C. The reactions were 
terminated by adding 50 μL of the reaction mixture onto a 2 x 2 cm square filter paper which is 
immediately immersed in 70% (v/v) ethanol to precipitate glycogen. Filter papers were washed 
twice in 70% ethanol for 30 minutes, dried and placed into scintillation vials containing 3 ml 
FLUKA scintillation cocktail and the amount of 
14
C determined. For each set of assays three 
blanks were prepared using buffer instead of tissue extract to determine background counts, 




2.2.8.2. Glycogen phosphorylase assay 
The glycogen phosphorylase assay was adapted from Taylor et al. (2006). Samples were 
weighed still frozen and homogenized (100 mg/ml) in an ice cold solution of 10 mM MOPS, 50 
mM NaF, 5mM EDTA, and 1 mM DTT, pH 7.0. The mixture was homogenized using an OMNI 
TH2 tissue homogenizer (USA) using a speed of 35 000 rpm at 4 ⁰C. The homogenates were 
centrifuged at 4°C for 10 minutes at 9000 g using a Beckman Coulter J26-XPI centrifuge (USA). 
Protein concentration was determined using the Folin-Lowry method and BSA used as a 
standard. Total GP activity was measured in the reverse direction by the incorporation of 
radiolabelled D-glucose-1-phosphate into glycogen at 30 °C.  The reaction was started by adding 
50 μL of sample to 50 μL of assay buffer containing 33 mM MES, 0.34% glycogen, 22.3 mM G-
1-P and 1 μCi/ml D-[U
14
C]-glucose-1-phosphate and incubating the mixture for 20 min. The 
reactions were terminated by adding 50 μL of the reaction mixture onto a 2 x 2 cm square filter 
paper which is immediately immersed in 70% (v/v) ethanol to precipitate glycogen. The filter 
papers were washed twice for 30 minutes in 70% ethanol, dried and placed into scintillation vials 
containing 3 ml FLUKA scintillation cocktail and the amount of 
14
C determined. For each set of 
assays three blanks were prepared using buffer instead of tissue extract to determine background 
counts, which were subtracted from the tissue extract counts.  The activity was expressed per mg 
of protein. 
2.2.8.3. Serum enzymes analysis 
Serum alanine transaminase (ALT) aspartate aminotransferase (AST) and lactate dehydrogenase 
(LDH) were measured using a Labmax Plenno biochemical analyzer, Brazil. AST catalyzes the 
transfer of the amino group from L - aspartate to α - ketoglutarate to yield oxaloacetate and L - 
glutamate. Malate dehydrogenase then catalyzes the reduction of oxaloacetate with simultaneous 
oxidation of NADH to NAD
+
. The resulting decrease in absorbance at 340 nm is directly 
proportional to AST activity. The ALT catalyzes the conversion of L-alanine and α - 
ketoglutarate to pyruvate and L-glutamate. LDH then catalyzes the oxidation of pyruvate with 
simultaneous oxidation of NADH to NAD
+
. The rate of decrease in absorbance of the reaction 
mixture at 340 nm, due to the oxidation of NADH is directly proportional to the ALT activity. 





 to NADH. The rate in change of absorbance at 340 nm is directly proportional to LDH 
activity. 
 
2.2.9. Biuret and Folin-Lowry assays for protein determination 
Protein concentration was determined using a modified biuret assay (Gornall et al., 1949). 
Protein standards were prepared using bovine serum albumin (BSA). The biuret reagent was 
prepared by dissolving 3 g of CuSO4.H2O and 9 g of KNaC4H4O4.H2O in 500 ml of 0.2 M 
NaOH. 5 g of KI was added and volume made up to 1 liter with 0.2 M NaOH. 3 ml of the biuret 
reagent was added to 2 ml of protein sample. The resulting solution was mixed and incubated for 
10 minutes at 37 ⁰C in a water bath. The tubes were cooled and the absorbance was read at 540 
nm using a Varian Cary 50 UV/Vis Spectrophotometer, USA. The protein standards were plotted 
against their known protein concentrations in the range of 0-10 mg/ml. A standard curve was 
drawn and the protein concentrations calculated. 
 
Protein concentration was also determined by using the Lowry method (Lowry et al., 1951). 
Solutions were prepared as follows: Alkaline sodium carbonate reagent (20 g/litre Na2CO3 in 0.1 
M NaOH) and copper sulphate-sodium potassium tartrate solution (5 g/litre CuSO4.5H2O in 10 
g/litre Na, K tatrate). On the day of the experiment alkaline reagent was prepared by mixing 
alkaline sodium carbonate solution and copper sulphate–sodium potassium tartrate solution 50:1 
whereas the Folin Ciocalteu reagent was prepared by diluting stock 1:2 with deionized water. To 
0.5ml of sample, 5 ml of alkaline reagent was added and incubated at 40 °C for 15 min. Samples 
were cooled followed by the addition of 0.5 ml Folin’s reagent, vortexing and incubation at room 
temperature for 30 minutes. Absorbance was read at 600 nm. BSA was used as a standard range 
(20 - 100 µg). The concentration of each sample was extrapolated from the standard curve graph. 
 
2.2.10. Determination of glycogen content 
The skeletal muscle and skin glycogen content was determined by a method adapted from Nader 
and Esser (2001). The tissues (0.5 g) were weighed and boiled for approximately 30 minutes in 1 
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ml of 30% KOH saturated with NaSO4. After the tissues were completely digested, glycogen was 
precipitated with 4 ml of 95% ice-cold ethanol and incubated on ice for 30 minutes. The tubes 
were centrifuged for 30 minutes at 20000 g. The pellets were re-suspended in 1 ml H2O followed 
by the addition of 5% phenol.  A known concentration of glycogen was used in place of the 
sample for the standards. A colorimetric reaction was obtained by the addition of 5 ml sulphuric 
acid followed by incubation on ice for 30 minutes. The absorbance was measured at 490 nm 
using an UVmini-1240, UV-VIS spectrophotometer (Shimadzu, Corporation, Kyoto, Japan). 
Water was used as a blank. The standard curve was constructed using glycogen in the range of 0-
100 µg/ml. 
2.2.11. Data analysis 
All data was expressed as mean ± standard error of mean (SEM). Statistical analysis was done 
using Graph Pad InStat Software (version5, GraphPad Software, San Diego, California, USA). 
Statistical comparisons of data between groups were done using one way one-way analysis of 
variance (ANOVA) followed by Turkey-Kramer multiple comparison test. Values of p< 0.05 






























H NMR spectra of OA dissolved in deuterated chloroform (i) from Sigma Aldrich and (ii) Shaanxi 











C (NMR) spectrums to compare OA 
from Sigma Aldrich that was used for the oral glucose tolerance test (OGTT) and that from 
Shaanxi Kingston Enterprise Limited Company which was used in the rest of the study due to the 
prohibitive cost of the former. In Table 3 are listed the 
13
C (NMR) peaks obtained for OA from 






C NMR spectra of OA in deuterated chloroform (i) from Sigma Aldrich and (ii) Shaanxi Kingston 







C (NMR) data comparison of OA from (i) Sigma Aldrich and from (ii) Shaanxi 
Kingston Enterprise Limited Company. 
















































Figure 3.2: Fasting (i) and non-fasting (ii) blood glucose levels of diabetic male Sprague –Dawley rats 
(n = 4) over a 2 hour period. (A) Shows the blood glucose concentrations expressed in mmol/L. (B) 
shows the blood glucose levels expressed as percentage variations from the blood glucose levels at 
time 0. The data  is represented as mean ± SEM. a p<0.05, DI compared  to DC, b p<0.05, DOI 
compared to DO, c p<0.05, DI compared to DO , d p< 0.05, DOI compared to DO and e p<0.05 DOI 








The effects of OA on fasting and non-fasting blood glucose levels of STZ induced diabetic rats 
were investigated. Figure 3.2 above shows the fasting and non-fasting blood glucose levels of 
diabetic male Sprague-Dawley rats over a 2 hour period. The blood glucose levels are expressed 
as mmol/L (A) and also as % variation in blood glucose levels from time 0 (B). OA did not 
reduce the blood glucose levels over the duration of the experiment in both the fasted and non-
fasted animals. The treatment of animals with insulin alone or with insulin in combination with 
OA caused a reduction in blood glucose levels. The fasted rats that were treated with OA + 
insulin had significantly lowered blood glucose levels (p<0.05) after 30 and 60 minutes of 
treatment when compared to the OA treated group. After 120 minutes, there was a significant 
lowering of blood glucose levels (p<0.05) by insulin ± OA when compared to the OA treatment 
and control in both the fasted and non-fasted animals. In the fasted rats OA enhanced the blood 
glucose lowering effect of insulin as there is a significant decrease in blood glucose levels 
(p<0.05) after 120 minutes in insulin + OA treated animals compared to those treated with 
insulin  alone.  
 
3.3. SDS-PAGE gels for muscle and skin homogenates  
 
Figure 3.3 below shows a representative SDS-PAGE gel of skeletal muscle and skin 
homogenates. The protein distribution in a 10% polyacrylamide reducing gel is shown for all the 
treatment groups. Of note are the high molecular weight proteins in skin homogenates which are 











3.4. Acute studies on effects of OA on expression of enzymes of the insulin signalling 
pathway 
 
Effects of OA on the activation of selected enzymes involved in the PI3-K/Akt insulin signalling 








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Figure 3.3: Coomassie stained 10% polyacrylamide SDS-PAGE reducing gel of skeletal muscle 
(lanes 2-9) and skin homogenates (lanes 10-17). Lanes: 1 (molecular weight marker) 2 and 10 
(NC), 3 and 11(DC), 4 and 12 (NI), 5 and 13 (DI), 5 and 16 (NO), 7 and 14 (DO), 8 and 16 




GS (Ser 641) and GS with GAPDH used as an loading control. Phospho-GS and GS were not 
detected in skin homogenates but phospho-Akt was detected at one time interval (30 minutes). 
 
3.4.1. Effects of OA on expression of phospho-Akt (p-Akt) in muscle 
 
After 15 minutes following treatment the expression of p-Akt was higher in diabetic animals 
compared to their respective treatment groups in non-diabetic animals (Figure 3.4.1 below). The 
highest expression of p-Akt was to be found in diabetic animals treated with insulin followed by 
the diabetic group treated with insulin plus OA and then the normal group treated with OA plus 
insulin and finally the diabetic group treated with OA. The level of p-Akt expression generally 
declined with time in all groups to reach lowest levels after 60 minutes. It is noted that 
expression levels were low in both control groups throughout the experimental period as did 
those in the normal groups treated within insulin or OA. Also of note is the independent 
activation of Akt phosphorylation by OA that declined with time to reach the lowest levels at 60 






Figure 3.4.1shows the expression of p-AKT after 15, 30, and 60 minutes following treatment.  
 
3.4.2 Effect of OA on expression of phospho-GS (p-GS) in muscle 
 
Figure 3.4.1: Western blots of (A) phospho-Akt (Ser 473) and (B) GAPDH in muscle homogenates 15, 30 and 
60 minutes following tr atment. 40 μg of rotein was loaded for A and 20 μg for B. (C) is the normalized data 
showing the ratio of phospho-Akt/GAPDH. The normalized data is grouped as non-diabetic and diabetic 
animals for clarity. 
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Figure 3.4.2: Western blot of (A) phospho-GS (Ser 641) and (B) GAPDH in muscle homogenates 15, 
30 and 60 minutes following treatment. 40 μg of protein was loaded for A and 20 μg for B. (C) is the 
normalized data showing the ratio of phospho-GS/GAPDH. The normalized data is grouped as non-






Figure 3.4.2 above shows the expression p-GS 15, 30 and 60 minutes following treatment. After 
15 minutes the expression of p-GS was higher in diabetic control animals and diabetic animals 
treated with insulin compared to non-diabetic animals that received the same treatment whilst p-
GS expressed in diabetic and non -diabetic animals that were treated with OA or OA plus insulin 
could not be quantified by densitometry. The p-GS was expressed in all the treatment groups 
after 30 minutes following treatment and all treatments had lower enzyme expression than the 
respective group controls showing net suppression of GS phosphorylation. The lowest p-GS 
expression was in the diabetic group treated with OA plus insulin, followed by the non-diabetic 
animals treated with insulin and then the diabetic animals treated with insulin. Non-diabetic 
animals that were treated with insulin or OA as well as diabetic animals treated with OA had the 
same p-GS expression. The p-GS expression after 60 minutes was generally low in all treatment 
groups.  
 
3.4.3 Effect of OA on expression of GS in muscle 
 
Figure 3.4.3 below shows the total GS expression 15, 30 and 60 minutes following treatment. 
After 15 minutes, the insulin treated diabetic and non-diabetic animals had high GS expression, 
with the highest expression being in the diabetic animals. Of note is that the enzyme expressed in 
diabetic and non-diabetic animals treated with OA plus or minus insulin could not be quantified 
by densitometry after 15 minutes following treatment. All the treatment groups had GS 
expressed after 30 minutes following treatment with expression being lower than that in the 
group controls. It was noted that GS expression in the normal OA plus insulin treated group, 
diabetic insulin and OA treated groups remained almost the same after 30 and 60 minutes 
following treatment. The changes in GS expression from 30 to 60 minutes following treatment 
showed that insulin treated normal animals had a slight decrease whilst there was a slight 
increase in normal OA treated animals. In diabetic OA plus insulin treated animals the change in 
expression was almost a 2 fold increase. The GS expressed in control groups after 30 and 60 










Figure 3.4.3: Western blot of (A) GS and (B) GAPDH in muscle homogenates 15, 30 and 60 minutes 
following treatment. 40 μg of protein was loaded for A and 20 μg for B. (C) is the normalized data 













The effect of OA on the expression of p-Akt in skin was investigated after 30 minutes following 
treatment (Fig 3.4.4). The p-Akt expression was higher in the normal treatment groups in 
compared to the respective treatments in diabetic animals. The highest p-Akt expression was that  
in insulin treated  normal animals, followed by insulin treated diabetic animals, then OA treated   
normal animals, OA plus insulin treated normal animals, OA plus insulin treated  diabetic 
animals and lastly OA treated diabetic animals. Of note is that, the loading control, GAPDH was 
not uniformly expressed and this might invalidate the normalization. 
 
3.5. Sub-chronic studies on expression of glycogenic enzymes 
 
Effects of OA on the expression of glycogen synthase and glycogen phosphorylase were 
investigated in skeletal muscle after 7 and 14 days of treatment. In skin the enzyme expression 
was investigated for animals treated for 14 days. GAPDH was used as a loading control. 
Glycogen synthase was not detected in skin homogenates. 
Figure 3.4.4: Western blots of (A) phospho-Akt (Ser 473) and (B) GAPDH in skin homogenates 
following 30 minutes treatment. 160 μg of protein was loaded for A and 80 μg for B. (C) is the 
normalized data showing the ratio of phospho-Akt/GAPDH. The normalized data is grouped as non-












Figure 3.5.1 above shows the GS expression following the sub-chronic treatment of the rats for 7 
and 14 days. Expression of GS was highest after 7 days of treatment in the normal animals 
treated with insulin and OA and this was the same trend after 14 days of treatment although GS 
expression had declined for these two groups. Normal animals treated with OA plus insulin had 
the lowest expression of GS amongst all groups after 7 days of treatment. The expression of GS 
in normal controls did not change over the 14-day period but that in diabetic control animals 
declined. There was an increase of GS expression in OA treated diabetic animals after 14 days of 
treatment.   
Figure 3.5.1: Western blots of (A) GS and (B) GAPDH in muscle homogenates after 7 and 14 days of 
treatment. 40 μg of protein was loaded for A and 20 μg for B. (C) is the normalized data showing the ratio 













The results in figure 3.5.2 show GP expression levels following sub-chronic studies for 7 and 14 
days in skeletal muscle. After 7 days of treatment GP expression was highest in normal animals 
treated with insulin, followed by normal animals treated with OA and diabetic animals treated 
with OA plus insulin. The GP expression levels in these groups declined drastically after 14 
days. The GP expressed in all the treatment groups was lowered after 14 days except in the 
Figure 3.5.2: Western blots of (A) GP and (B) GAPDH in muscle homogenates after 7 days of 
treatment. 40 μg of protein was loaded for A and 20 μg for B. (C) is the normalized data showing the 





insulin treated diabetic animals in which it increased substantially. The GP expressed in the 
control animals was more or less the same after 7 days and after 14 days.   
 






Figure 3.5.3 above shows the GP expression in skin following 14 days of treatment. GP 
expression was highest in insulin treated non-diabetic animals, followed by insulin treated 
diabetic animals and OA treated non-diabetic animals. Treatment of non-diabetic and diabetic 
animals with OA plus insulin caused a decline in GP expression when compared to animals 
treated with insulin. GP expressed in the diabetic control group could not be quantified by 
densitometry. The low expression of GAPDH in the diabetic control and insulin treated diabetic 







Figure 3.5.3: Western blots of (A) GP and (B) GAPDH in skin homogenates after 14 days of 
treatment. 220 μg of protein was loaded for A and 20 μg for B. (C) is the normalized data showing the 





3.6. Glycogen synthase and phosphorylase activity 
 
Effects of OA on the activities of glycogen synthase and phosphorylase in skeletal muscle and 
skin after 14 days of treatment were determined. 
 









































The results in figure 3.6.1a show skeletal muscle GS activity following 14 days of treatment. GS 
activity was slightly lower in diabetic control animals compared to normal control animals. The 
diabetic animals treated with OA plus animals had significantly elevated GS activity in 
comparison to the controls.  Treatment of normal and diabetic animals with insulin also lead to 
higher GS activity while treatment with OA caused a slight increase in GS activity compared to 
their respective controls.   
 
Figure 3.6.1a: Muscle glycogen synthase activities after 14 days of treatment in non-
diabetic and diabetic male Sprague-Dawley rats (n = 6). Data is represented as mean 


















































Figure 3.6.1b above shows skin GS activity following the 14 day sub-chronic study. There was 
slightly higher GS activity in diabetic control animals compared to normal control animals. In 
both non-diabetic and diabetic animals the OA plus insulin treatment groups had significantly 
elevated GS activity when compared to their respective control groups. The highest GS activity 
was in the non-diabetic insulin treated group which was followed by diabetic OA plus insulin 
treated animals. The insulin treated diabetic animals and OA treated non-diabetic rats had 
slightly higher GS activities compared to their controls. The non-diabetic insulin treated and 








Figure 3.6.1b: Skin glycogen synthase activity after 14 days of treatment in non-diabetic and 
diabetic male Sprague-Dawley rats (n = 6). Data is represented as mean ± SEM. * p<0.05 






















































The results in figure 3.6.2a show the skeletal muscle GP activity after the 14 day sub-chronic 
study. GP activity was slightly higher in normal control animals compared to diabetic control 
animals. Treatment with OA did not cause a change in GP activities for both diabetic and non-
diabetic animals but treatment with OA plus insulin reduced GP activity to levels below their 
controls.  The GP activity of insulin treated diabetic animals was significantly higher when 
compared to the GP activity of normal control animals.  
 
 
Figure 3.6.2a: Muscle glycogen phosphorylase activity after 14 days of treatment in non-
diabetic and diabetic male Sprague-Dawley rats (n = 6). Data is represented as mean ± SEM. 






















































The activity of GP in the skin is shown in Figure 3.6.2b. The diabetic control animals had lower 
GP activity compared to normal control animals. GP activity was significantly elevated in the 
OA plus insulin treated diabetic animals when compared to diabetic control animals. Treatments 
in the non-diabetic animals reduced GP activity whilst in diabetic animals treatments increased 










Figure 3.6.2b: Skin glycogen phosphorylase activity after 14 days of treatment in 
non-diabetic and diabetic male Sprague-Dawley rats (n = 6). Data is represented as 





3.7. Glycogen content 
 
Table 3.2 below shows the amount of glycogen in skeletal muscle and skin following the 14 days 
sub-chronic study. Diabetic control animals had a slightly higher amount of glycogen compared 
to the non-diabetic control animals. The amount of muscle glycogen was slightly higher in the 
treated diabetic animals except the OA plus insulin treated diabetic animals when compared to 
the diabetic control animals. The highest amount of glycogen was in the insulin treated diabetic 
animals and followed by the OA treated diabetic animals. All the other treatment groups had 
lower amounts of glycogen than the non-diabetic control animals. The highest amount of 
glycogen was in non-diabetic insulin treated animal and diabetic OA plus insulin treated animals 
which had the same amount of glycogen. This was followed by the normal animals treated with 
insulin and lastly normal animals treated with OA plus insulin. The amount of glycogen in skin 
was slightly elevated in diabetic animals compared to their respective treatments in non-diabetic 
animals. The amount of glycogen was higher in the diabetic OA treated animals compared to the 
diabetic control group whilst OA plus insulin treated diabetic animals and insulin treated diabetic 
animals had lower amounts of glycogen. The treated non-diabetic animals had slightly lower 
amounts of glycogen compared to the non-diabetic control animals. The highest amount was in 










Table 3.2: The effect of different treatments on skeletal muscle and skin glycogen levels after 14 days of treatment in non-diabetic 
and diabetic male Sprague-Dawley rats. Values are represented as mean   SEM (n=5) 
 
 










1.08  0.07 1.02  0.06 1.05  0.04 
 
1.07  0.04 
 
      0.12 
 
1.15  0.09 
 
1.37  0.12 
 
1.21  0.04 
 
 
# p < 0.05 compared to DC
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3.8. Serum enzyme analysis 
 
The results in Table 3.3 below show the levels of LDH, ALT and AST after the sub-chronic 
study. The diabetic animals had higher LDH levels than their respective treatment groups in the 
normal animals. Insulin and OA treated animals showed slightly higher LDH levels in both non-
diabetic and diabetic animals compared to their respective controls. However LDH levels were 
decreased in OA plus insulin treated normal and diabetic animals compared to their respective 
controls. The level of serum ALT was higher in all the diabetic animals, compared to their 
respective treatment groups in the normal animals. The ALT levels were decreased in all the 
treatment groups for non-diabetic and diabetic animals compared to their respective controls 
except for the insulin treated diabetic animals. Insulin treated diabetic animals had increased 
ALT levels compared to the diabetic control group. Non-diabetic treated animals had lower ALT 
levels compared to the non-diabetic control animals. In all the groups, there was a higher level of 
AST in the diabetic treatment groups compared to the respective treatments in non-diabetic 
animals. The level of AST was higher in all the normal treatment groups compared to the non-
diabetic control group. The highest AST level was in the insulin treated animals, followed by OA 
treated animals and then OA plus insulin treated animals. All the treatment groups in the diabetic 
animals had reduced AST levels compared to the diabetic control group. Of note is that OA 
reduced LDH, ALT and AST in both diabetic and non-diabetic animals compared to their 




Table 3.3: The effect of different treatments on serum LDH, ALT and AST levels after 14 days of treatment in non-diabetic and 
diabetic male Sprague-Dawley rats Values are represented as mean   SEM (n=5) 
 NC NI  NO NOI 
 
DC DI DO DOI 
LDH 
(U/L) 
1035  130 1258  54.4 
 
1063   86.1 
 
788.4  50.6 1167  52.5 
 
1270  139 
 
1045  92.4 
 
786.5  97 
ALT 
(U/L) 
75.8  5.9# 
 
67.17  1.4# 
 
71  2.8# 
 
69.4  3.2# 
 
170.6  12.3* 
 
188.3  10.1* 156.7  8.6* 
 




133.3  12#  
 
185.5  7.6 
 
158.2  8.5# 
 
138.8  7.6# 
 




163.8  14.8# 
 
145.5  8.7# 
 
 
* p < 0.05 compared to NC 














Diabetes mellitus is one of the diseases with a high mortality rate of about 3 million deaths per 
year according to World Health Organization (WHO). Type 1 diabetes which is caused by 
pancreatic β cell destruction accounts for 5-10% of all diabetes cases and patients suffering from 
the disease need exogenous insulin (Adams et al., 2011). Diabetes (both type 1 and type 2) is 
characterized by chronic hyperglycaemia, thus treatment of diabetes focuses on glycaemic 
control. Chronic hyperglycaemia can directly contribute to glucose-induced insulin resistance 
(glucose toxicity) in both forms of diabetes. The high levels of glucose can result in this 
resistance due to activation of protein kinase (PKC) which leads to increased serine/threonine 
phosphorylation of the IR. Serine/threonine phosphorylation of the IR reduces its tyrosine 
phosphorylation  which in turn reduces downstream insulin-stimulated IRS1 phosphorylation and 
PI3K activation (Zierath and Kawano, 2003). Hyperglycaemia can also directly impair insulin 
action on Akt. High concentrations of glucose are associated with modifications of PI3K, Akt 
and GS suggesting a mechanism by which glucose can directly alter the signalling properties of 
signalling intermediates and enzymes (Steiler et al., 2003). Hyperglycaemia also induces 
oxidative stress, which leads to tissue damage (Giacco and Brownlee, 2010), and has been 
hypothesized to contribute to oxidative stress by the direct generation of reactive oxygen species 
(ROS) or by altering the redox balance (Rains and Jain, 2011).  
 
The study investigated the effects of OA in vivo on the insulin signalling cascade in different 
diabetic pathologies in muscle and skin. Normal animals were subjected to hyperinsulinaemic 
conditions by being given an insulin dose. Hyperinsulinaemia is implicated in causing insulin 
resistance in skeletal muscle (Björnholm and Zierath, 2005). Treatment of normal animals with 
insulin plus OA investigates whether OA can prevent insulin resistance due to 
hyperinsulinaemia. OA treatment of normal animals investigated whether OA might have 
detrimental effects in non-diabetic as it is used to treat other ailments such as hepatitis (Song et 
al., 2006). Treatment of diabetic animals with OA investigated whether the compound has 
insulin mimetic capabilities. It has been suggested that OA enhances the effects of insulin in 
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vitro (Wang et al., 2011) and thus treatment of diabetic rats with OA + insulin investigated the 
hypothesis in vivo. The skeletal muscle accounts for 75% of glucose disposal (Jensen et al., 
2011a) and most of the glucose is converted to glycogen storage. The activities of enzymes (GS 
and GP) that regulate the levels of glycogen were investigated as well as the deposition of 
glycogen after treatments. The skin is the largest tissue in the body and its contribution to 
glucose utilization has not been elucidated. The skin was studied as it might contribute to glucose 
homeostasis in normal and diabetic animals particularly those undergoing treatment.   
 
The results in Figure 3.2 suggest that OA does not reduce fasting and non-fasting blood glucose 
levels in STZ induced diabetic rats. An experiment by Zeng et al. (2012) also showed that OA 
did not reduce blood glucose levels after treatment for 2 weeks in a type 1 diabetes model in 
mice, though it did reduce blood glucose levels which was sustained for six weeks in a type 2 
model of diabetes. Studies conducted by Gao et al. (2009) and Ramírez-Espinosa et al. (2011), 
showed a decrease in blood glucose levels in vivo in a type 2 model of diabetes starting an hour 
after treatment. One of the investigated hypoglycaemic actions of OA is its inhibition of PTP1B 
(Elchebly et al., 2000; Li et al., 2012; Liu et al., 2010; Ramírez-Espinosa et al., 2011). PTP1B 
inhibition improves insulin sensitivity by blocking the PTP1B-mediated regulation of the insulin 
signalling pathway (Thareja et al., 2012). Our results suggest that when OA is used in 
combination with insulin in type 1 diabetic rats there is a synergistic enhancement of the insulin 
mediated reduction of fasting blood glucose levels.  
 
Results in Figure 3.4.1 showed that in vivo insulin mediated Akt phosphorylation, was achieved 
in both non-diabetic and diabetic rats. Insulin stimulated Akt phosphorylation is higher in 
diabetic animals compared to non-diabetic animals. This might be due to an increase in insulin 
receptor expression or sensitivity in diabetes. It has been reported that there is an increase in 
insulin receptor expression and tyrosine kinase activity in the heart of STZ induced type 1 
diabetic rats (Laviola et al., 2001), and an increase in insulin stimulated IR and IRS-1 
phosphorylation has been demonstrated in skeletal muscle and liver of diabetic rats (Wang et al., 
1999). An experiment by Oku and co-workers in 2001 showed that insulin stimulated tyrosine 
phosphorylation of the insulin receptor was increased by 39 % STZ induced diabetic rats 
compared to normal animals (Oku et al., 2001). Insulin stimulated phosphorylation of IRS1 and 
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IRS2 was also increased by 76 an 89 % respectively in STZ induced diabetic rats compared to 
normal rats (Oku et al., 2001). This may lead to the higher Akt phosphorylation levels due to 
insulin treatment in the diabetic animals. Insulin treatment of non-diabetic rats can also lead to 
hyperinsulinaemia. Hyperinsulinaemia has been implicated in causing insulin resistance (Thirone 
et al., 2006) which can lead to a decrease in insulin stimulated phosphorylation of Akt (Wang et 
al., 2011) which might account for the low pAkt expression in normal animals treated with 
insulin. Studies by Feng et al. (2011) showed that OA can activate Akt in vascular smooth 
muscle cells. OA has also been shown to enhance insulin stimulated activation of Akt in 
hepatocytes at certain concentrations (Wang et al., 2011). Our results show that OA can activate 
Akt phosphorylation which suggests that it can influence certain proteins of the insulin signalling 
pathway independently of insulin.  In the current study we also show that a combinational 
treatment of the diabetic rats with OA and insulin leads to the enhancement of the insulin 
mediated Akt activation in 15 minutes following treatment and this might be when the OA 
concentration is optimum in the animal. This is quite remarkable considering that OA was 
administered orally. 
 
 In the skin (Figure 3.4.4) Akt phosphorylation was slightly increased by insulin treatment in 
non-diabetic animals whilst it was slightly decreased in diabetic animals compared to their 
respective controls. Insulin stimulated Akt activation has been shown in intact rat skin fragments 
from normal rats (Pelegrinelli et al., 2001). Our results show Akt phosphorylation was after 30 
minutes following treatment thus insulin might not have reached the target organ and thus 
delayed insulin-stimulated Akt phosphorylation in diabetic rats or diabetes might also cause 
desensitization of insulin receptors in the skin. However the loading control, GAPDH was not 
fully expressed in the control and insulin treated animals of both the non-diabetic and diabetic 
animals. This might affect the normalization of our data. OA treatment also led to a suppression 
of insulin stimulated-Akt phosphorylation in both non-diabetic and diabetic rats.  
 
Insulin is attributed with the net suppression of GS phosphorylation thus activating the enzyme 
(Mandarino et al., 1987; Villar-Palas and Guinovart, 1997). Our results in Figure 3.4.2 show that 
there was little non quantifiable expression of p-GS in OA or OA plus insulin treated animals 
after 15 minutes following treatment. In animals where OA was not included in the treatment, 
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expression of p-GS was low for this time period. After 30 minutes following treatment, p-GS 
was expressed in all animal groups at generally elevated levels with diabetic control animals 
having the highest expression followed normal control animals. At 60 minutes, expression levels 
of phosphorylated of GS were almost the same across all animal groups. Thus there appears to be 
biphasic expression in which activation is followed by suppression. What is clear is that at 30 
minutes treatment of normal and diabetic animals with insulin, OA and OA plus insulin 
suppresses phosphorylation of GS which would be expected to activate GS and hence promote 
glycogen synthesis. Our results have shown that OA activates Akt on its own which might lead 
to the downstream suppression of GS phosphorylation and this appears to be the case at 30 
minutes following treatment of animals with OA.  
 
Sub-chronic studies on GS expression studies showed a decrease in GS expression in the diabetic 
control rats compared to non-diabetic control rats after 14 days of treatment. After treatment with 
insulin or OA, GS expression in skeletal muscle of normal animals was increased. Skeletal 
muscle glycogen synthase mRNA expression has been shown to increase due to insulin treatment 
(Huang et al., 2000). Treatment of non-diabetic rats with a combination of both insulin and OA 
led to an inexplicable decrease in GS expression. In the diabetic animals GS expression, after 14 
days, was increased by all the treatments. The shorter time period of treatment and diabetes 
development might account for the differing GS expression levels after 7 days.  
 
Our results in figure 3.5.2 show that GP expression levels in muscle are lower in diabetic control 
animals after 14 days compared to the non-diabetic animals. GP mRNA expression is 
destabilized by diabetes in rat liver leading to lower protein levels (Rao et al., 1995). After 14 
days the treatments in normal animals reduce the GP expression levels. In rat liver GP mRNA 
expression in diabetic animals is normalized with chronic insulin treatment (Rao et al., 1995). 
Our results show that treatment of diabetic animals with insulin increases GP expression whilst 
OA + insulin reduces the expression. To our knowledge expression of GP and the effects of 
diabetes or insulin on GP expression in the skin have not been documented. The results (Figure 
3.5.3) show that the GP encoded by the PYGM gene (present in skeletal muscle) was also 
present in the skin. GP which was expressed in the diabetic control animals could not be 
quantified. In the diabetic control and diabetic animals treated with insulin, there was also a 
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matching low expression of the loading control, GAPDH. Insulin and OA   insulin treatment 
increased GP expression in both normal and diabetic animals. We cannot be certain on the effect 
of treatments the diabetic animals as we could not quantify the GP expressed in the control group 
could not be quantified as well as the low expression of the loading control..  
 
Skeletal muscle GS activity has been shown to be decreased in diabetic rats (Farrace and 
Rossetti, 1992; Vestergaard et al., 1994) and this is confirmed  by  our results in Figure 3.6.1a 
which show a 22% decrease in GS activity in the diabetic animals when compared to the non-
diabetic rats. Treatment of the normal animals with insulin, OA and OA + insulin leads to a 33%, 
16% and 21% increase in GS activity respectively when compared to the normal control animals. 
Treatment of the diabetic animals with insulin, OA and OA + insulin leads to an 87%, 14% and 
195% increase in GS activity respectively with the increase in the OA plus insulin treatment 
group being significant. In diabetes insulin-stimulated GS activation is impaired, though under 
hyperglycaemic conditions the insulin-stimulated GS activity is enhanced opposite has been 
shown (Farrace and Rossetti, 1992). Hyperglycaemia has been shown to activate GS  (Wright et 
al., 1988) due to its increase of G-6-P concentrations (Farrace and Rossetti, 1992; Wallis et al., 
1998). G-6-P is an allosteric activator of GS and an increase in its content has been shown to 
increase GS activity (Yki-Jirvinen et al., 1987). In studies by Farrace and Rossetti in 1992 there 
was a marked stimulation of GS activity in pancreatomized type 1 diabetic rats compared to  
normal rats which is due to the hyperglycaemic condition that can stimulate GS activity. In our 
study there was stimulation of GS activity in diabetic animals by insulin and OA treatments 
while OA plus insulin treatment resulted in a synergistic effect that increased the high GS 
activity.   
 
GS activity has been measured in dog and mouse skin samples and found to be a fifth of the 
activity in the liver (Adachi, 1961). To our knowledge the effect of diabetes or insulin on the 
skin GS activity has not been documented. Figure 3.6.1b shows that in skin there is a 9% 
increase in GS activity for the diabetic control group when compared to the normal control 
group. Treatment in the normal animals with insulin leads to a 28% decrease in GS activity when 
compared to the normal control animals. OA and OA plus insulin treatment of normal animals 
lead to a 22% and 259% increase in the glycogen synthase activity respectively when compared 
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to the normal control animals. Our results show that in diabetic animals, insulin and OA 
+`insulin treatment increases GS activity (26% and 100% respectively) compared to the diabetic 
control group. OA treatment on the other hand leads to a 25% decrease GS activity when 
compared to the diabetic control group. The OA plus insulin treated diabetic animals had high 
GS activity which corresponds with the high GS activity observed in our muscle samples after 
the same treatment. The results also suggest that there was insulin stimulated GS activity in the 
skin of diabetic animals as there was an elevation of GS activity. 
 
Glycogen phosphorylase activity is increased by 14% in the diabetic control group when 
compared to the normal control group as shown in Figure 3.6.2a. Non-diabetic and diabetic 
animals showed increased GP activity but very little change occurred with OA treated animals. 
However, a combination of OA plus insulin caused a 9% and 11% decrease in GP in normal 
animals and diabetic animals, respectively when compared to their respective controls. Insulin 
treatment of the non-diabetic and diabetic animals, lead to a 30% and 15% increase in GP 
activity respectively when compared to the respective control groups. GP activity has been 
shown to be increased in STZ-induced diabetes (Sadek, 2011). In liver insulin increases the 
stability of phosphorylase mRNA thereby increasing protein levels and total activity (Rao et al., 
1995). The results from the study suggested that there was an increase in GP activity due to 
diabetes and also an insulin stimulated increase in GP activity. Our results also show that OA has 
no inhibitory effects of GP activity in vivo. This is contrary to studies that have reported the 
inhibitory activity of OA on GP in in vitro studies (Liu et al., 2010; Wen et al., 2008). 
 
The activities of both the a and b form of GP been demonstrated in skin of dogs and mouse 
(Adachi, 1961). The effect of diabetes or insulin on the GP activity in skin has not been 
documented. In the skin GP activity was lowered in diabetic control animals by 70% when 
compared with the normal control animals as shown in Figure 3.6.2b. Treatment with insulin, 
OA and OA   insulin causes a 44%, 16% and 32% decrease in GP activity, respectively in the 
normal animals. Insulin and OA treatment of diabetic animals increases GP activity by 97% and 
17% respectively when compared to the diabetic control animals. OA + insulin treatment in 
diabetic animals caused a significant 291% increase in GP activity when compared to the 
diabetic control group. Our results suggested that insulin was able to increase the activity of GP 
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and this effect was enhanced by OA. On its own OA was also able to slightly increase GP 
activity. The results suggest that in skin GP is regulated differently muscle GP.  
 
The results in Table 3.1 show that muscle glycogen is increased in diabetic control animals by 
20% when compared to the normal control animals. In human diabetes glucose stimulates its 
own uptake in skeletal muscle with normal or improved efficiency and hyperglycaemia may 
exert a compensatory homeostatic mechanism that normalizes glucose disposal (Farrace and 
Rossetti, 1992). It has been shown that hyperglycaemia stimulates glucose storage in diabetic 
individual (Farrace and Rossetti, 1992) which can account for the higher glycogen content in our 
results. Treatment in normal animals with insulin, OA and OA + insulin decreased the glycogen 
content by 15%, 20% and 26%, respectively. When the glycogen store in muscle is replete, the 
glucose taken up is converted to lactate, in order to maintain enhanced glucose utilization. The 
lactate is taken up by the liver and converted to glycogen (Dimitriadis et al., 2011). This might 
account for the decrease in glycogen content in the non-diabetic animals treated with insulin and 
there was also an increase in the GP activity which would contribute to the decrease in the 
amount of glycogen. A combination of OA plus insulin treatment in the diabetic animals leads to 
a significant decrease (28%) in the glycogen content compared to the diabetic control group. 
Though there is an increase in GS activity and decrease in GP activity there was a decrease in 
glycogen content with OA + insulin treatment. This might be due to the maximum catalytic 
capacity of glycogen phosphorylase being approximately 50-fold greater than that of glycogen 
synthase in human skeletal muscle. Consequently, phosphorylase must be inhibited by 
approximately 99% of its maximum activity for net glycogen synthesis to occur (Dimitriadis et 
al., 2011). Work conducted by Ngubane et al. (2011) also showed that treatment with OA and 
insulin leads to a decrease in hexokinase activity in skeletal muscle of diabetic rats which would 
lead to a decrease in G-6-P. G-6-P is an allosteric activator of GS (Bouskila et al., 2008), 
therefore reduction in its concentration would lower glycogen synthesis. Individual insulin and 
OA treatment lead to an increase in glycogen content (14% and 8% respectively) in the diabetic 
animals with when compared to the diabetic control group. In the diabetic state there is a lower 
plasma insulin concentration and this might lead to a slight increase in glycogen content. 
Dimitriadis and co-workers in 2011 suggested that at low physiologic plasma insulin levels, 
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insulin increases the net rate of glycogen synthesis by inhibiting phosphorylase activity rather 
than activating glycogen synthase. 
 
Our results show that there is GS and GP activity as well as expression of GP in skin which 
suggests the presence of glycogen in this tissue. The presence  of glycogen in skin dogs was 
shown by (Adachi, 1961) and this  glycogen is used in hair growth and production of sweat. The 
effect of diabetes and insulin on skin glycogen deposition has not been documented though. 
Results in Table 3.2 show that skin has glycogen content which is 22% higher in the diabetic 
control animals compared to the normal control animals. In our study we observed that GP 
expression levels in the skin of the diabetic control group are also very low which might lead to 
limited breakdown of the glycogen present. Our results also show that there was higher GS 
activity and lower GP activity for diabetic control animals. The amount of glycogen in normal 
and diabetic animals is not significantly altered by the different treatments when compared 
respective control groups. Our study also showed that the glycogen levels in skin are comparable 
to muscle glycogen in terms of amount. These are 5 times higher than the glycogen amounts 
found in dog skin by Adachi in 1961 probably due to improved extraction methods over the 
years. 
 
Muscle and liver dysfunction is frequently associated with diabetes mellitus. Many clinical 
reports have indicated that activities of serum enzyme derived from the muscle such as creatine 
phosphokinase (CPK), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) are 
elevated. A study conducted on 20 hyperglycaemic alloxan induced diabetic male white New 
Zealand rabbits showed that LDH levels were significantly increased (Celik et al., 2002). In our 
study untreated diabetic animals had a 13% increase in LDH compared to the normal control 
animals. Normal animals treated with insulin or OA had 22% and 3% increase in LDH 
respectively compared to the normal control whilst OA plus insulin treatment of the normal 
animals lead to a 24% decrease. Compared to the diabetic control group insulin treatment in 
diabetic animals increased the LDH levels by 9% whilst OA or OA plus insulin decreased the 
LDH levels by 10% and 37% respectively. The results suggest that OA and insulin might have 




In STZ induced type 1 diabetes mellitus ALT levels are elevated showing liver damage (Ragbetli 
and Ceylan, 2010; West et al., 2006). Table 3.3 shows that there is a significant increase of ALT 
levels (125%) in the diabetic control group when compared to normal control group. Insulin, OA 
and OA + insulin reduces the ALT levels by 11%, 6% and 8% respectively when compared to 
the normal control group. In the diabetic animals insulin increases the ALT levels by 10% when 
compared to the diabetic control group. OA and OA + insulin treatments reduce the ALT levels 
by 11% and 12% respectively when compared to the diabetic control group. Work conducted by 
Takaike et al. (2004) showed that liver transaminases are slightly elevated at the start of insulin 
treatment in diabetic ketosis or diabetic ketoacidosis. Echo-histogram analysis on patients with 
transient elevation of liver transaminases after insulin treatment was conducted and the results 
suggested fat deposition in the liver. They suggested that fat deposition might be one of the 
causes of the mild increase in AST/ALT after initial insulin treatment (Takaike et al., 2004). The 
deposition of fat in the liver leads to increase in gluconeogenesis and a decrease in storage of 
glucose as glycogen in the liver (Ford et al., 2008). Increases  in serum transaminases in diabetic 
animals has been  attributed to cetogenesis and/or hepatic lesions (Ragbetli and Ceylan, 2010). 
Our results suggest that OA can ameliorate liver damage and prevent leaking of the enzymes 
from hepatocytes as evident from its lowering of serum ALT levels. In a study by Gao and co-
workers in 2009, ALT was significantly increased the alloxan induced diabetic rats compared to 
the normal rats. After 40 days of treatment with OA, the ALT levels were significantly reduced 
compared to those in the diabetic control group.   
 
AST is an enzyme primarily localized not only in the liver but also in skeletal and myocardial 
muscle. Our results show an elevation of the enzyme in the diabetic groups compared to the non-
diabetic groups. There is a significant 78% increase in the serum AST levels of the diabetic 
control group when compared to the normal control group as shown in Table 3.3. Treatment of 
normal animals with insulin lead to a 39%, 19% and 4 % increase in AST levels respectively 
when compared to the normal control group whereas  treatment of the diabetic animals with 
insulin, OA and OA + insulin leads to a 9%, 31% and 39% decrease in serum AST levels 
respectively when compared to the diabetic control group. Rhabdomyolysis (the breakdown of 
skeletal muscle tissue rapidly) can result from direct and indirect damage to muscle membrane 
and may lead to leakage of intracellular muscle components into the extracellular fluid 
64 
 
(Brancaccio et al., 2010). Diabetic ketoacidosis is one of the causes of rhabdomyolysis. 
Disorders in carbohydrate metabolism or an augmented metabolic demand resulting in a hyper 
metabolic state lead to a reduction in the availability of ATP and the impairment of Na-K 
ATPase. This results in decreased membrane resistance from increased internal free calcium ions 
which promotes the activation of intracellular proteases (Brancaccio et al., 2010). Our results 
suggest that OA and OA + insulin might reduce muscle damage as shown by the reduction in 





















From the study OA was shown to have no hypoglycaemic effect in a type 1 diabetic model over 
a 2 hour period but might enhance insulin stimulated glucose uptake. It was observed that OA 
can activate Akt and suppresses phosphorylation of GS in skeletal muscle of diabetic rats in an 
insulin independent manner. OA in synergy with insulin was able to enhance insulin-stimulated 
suppression of GS phosphorylation skeletal muscle of diabetic rats. In the skeletal muscle of 
diabetic animals OA increases GS expression and lowers GP expression and GP encoded by the 
PYGM gene was expressed the skin. The treatment of diabetic animals with OA leads to an 
increase in both GS and GP activities in skeletal muscle, whilst in skin the activities of both GS 
and GP were lowered. In both skeletal muscle and skin of diabetic rats, OA increased the 
glycogen content. OA might also have tissue protective effects as it lowers LDH, AST and ALT 
levels in diabetic rats. In conclusion, OA in synergy with insulin can enhance activation of the 
insulin signaling pathway and thus has potential in treatment of type 2 diabetes, and secondly 
OA can also potentially regulate enzymes involved in the insulin signaling pathway in an insulin 
independent manner in vivo. 
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Appendix 1: Biuret assay standard curve 
  








































Appendix 2: Folin-Lowry assay standard curve 
 







































Appendix 3: Glycogen determination standard curve 
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